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ABSTRACT 
In vitro microphysiological system for modeling vascular disease 
HaYeun Ji 
 
In vitro microphysiological system utilizes engineered tissue constructs from human cells 
to model functional activity of human tissues or organs in both healthy and diseased state, 
thereby providing a more accurate drug screening than animal models prior to clinical trials. One 
essential component of an in vitro microphysiological system is a tissue engineered blood vessel 
(TEBV) that can accurately recapitulate the functional vasculature in vivo. This thesis first 
explores two most important considerations to a successful TEBV generation, the cell source and 
the fabrication method. To engineer a vascular tissue construct, an ideal cell source should 
demonstrate high availability and accurate vessel functionality. Mesenchymal stem cells (MSC) 
were explored due to their high availability, proliferation capacity, and capability to deposit 
adequate extracellular matrix (ECM) for cell sheet formation. Vascular smooth muscle cells 
(SMC) are the cell components that comprise the medial layer of native blood vessel, and thus 
optimal for demonstrating equivalent biological functionality. However, SMC are much harder 
to acquire through biopsy, and they have limited proliferative capacity and quick senescence. 
Therefore, an alternative cell source for SMC was obtained through direct reprogramming 
approach involving the induced overexpression of myocardin in more readily available human 
cell sources. The resulting reprogrammed SMC demonstrated close resemblance to the native 
SMC in terms of its phenotype, related gene and protein expression levels, and contractile 
function. Two different fabrication methods, nanopatterned cell sheets and dense collagen 
hydrogel, were explored to engineer a 1 mm inner diameter blood vessel. The fabricated TEBVs 
were then compared to that of the native blood vessel and each other in terms of its structure, 
mechanical properties, and vasoactive function in response to stimuli.  
After selecting the most optimal cell source and fabrication method for developing a 
human cell-based TEBV for in vitro microphysiological system, the second part of this thesis 
assesses the capability of the designed TEBV to model a vascular disease for drug screening 
purposes. Marfan syndrome was selected as a model vascular disease due to its previous history 
of contradictory results from the animal models and human clinical trials using losartan, an 
angiotensin II receptor blocker, in terms of preventing aortic root dilation. TEBV fabricated 
using reprogrammed SMC from Marfan syndrome patient sample and dense collagen hydrogel 
showed reduced fibrillin deposition, increased vessel diameter and thickness, and reduced 
vasoconstriction levels when compared to the wild type TEBV, which is consistent with that 
observed in native vessels of Marfan syndrome patients. Losartan improved the function of 
Marfan syndrome TEBV, but still at reduced level when compared to that of the wild type. 
SB203580, a selective inhibitor of p53 MAPK that has been shown to be a better drug candidate 
than losartan in recent cell-based studies, showed improved TEBV function comparable to that 
of the wild type.  In overall, this thesis presents a successful development of a highly robust, 
patient-specific in vitro vascular model. An accurate recapitulation of a drug-induced 
physiological response in humans can speed up the drug screening process with higher 
efficiency, and this will eventually increase the chances of successful treatment for patients. 
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Chapter 1. Introduction 
1.1 Specific Aims 
In vitro microphysiological system utilizes bioengineered chips and engineered tissue 
constructs from human cells to model functional activity of human tissues or organs in both healthy 
and diseased state. Currently most drug development and in vitro disease modeling studies rely 
heavily on 2-D cell cultures and animal models for pre-clinical studies. However, 2-D cell cultures 
fail to provide the complexity of the native 3-D microenvironment that is crucial for cell processes, 
and animal models do not completely recapitulate the complex physiology of human disease state 
due to cross-species discrepancy. Therefore, there is an emerging trend to develop in vitro 
microphysiological systems that can provide a more biomimetic human-based pre-clinical analysis. 
An accurate modeling of a drug-induced physiological response in a disease state can speed up the 
drug screening process with higher efficiency, and this will eventually increase the chances of 
successful treatment for patients.  
One essential tissue component of an in vitro microphysiological system for drug screening 
is the blood vessels. At present, most of the integrated microphysiological system that composes 
of multiple organ components uses plastic channels as connections. However, this is not an 
accurate recapitulation of the in vivo transport system. A functional vasculature with a smooth 
muscle cell layer and an intact endothelium is necessary not only to allow proper gas and nutrient 
transport, but also to prevent diseases caused by failure to maintain proper vascular tone and 
regulation. Furthermore, because a lot of drugs are administered intravenously, the toxicological 
evaluation of drug-induced vascular injury is crucial. As such, there is a great need for developing 
a functional tissue engineered blood vessel (TEBV) suitable for in vitro microphysiological system.   
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Two most important considerations to a successful TEBV generation are the cell source 
and the fabrication method. To engineer a tissue construct, it is necessary to acquire a large quantity 
of human cells. In that sense, the high availability and proliferation capacity of mesenchymal stem 
cells (MSC) make them an excellent cell source for the medial layer of the TEBV. On the other 
hand, for a TEBV to demonstrate biological functionality equivalent to that of the native blood 
vessel, it is most optimal to use smooth muscle cells (SMC). However, SMC are much harder to 
acquire through biopsy, and they have limited proliferative capacity and quick senescence. 
Therefore, finding an alternative cell source for SMC is necessary. One promising method is to 
apply direct reprogramming of one somatic cell into another. While various fabrication methods 
exist for creating a vascular tissue construct, here we explore two different methods: the scaffold-
free, cell sheet TEBV and the dense collagen hydrogel.  
For a developed TEBV system to be successful in providing an accurate pre-clinical 
analysis, the system needs to demonstrate its capability to model a vascular disease and depict 
drug-induced physiological response. Marfan syndrome (MFS) is a vascular disease caused by a 
mutation in FBN1 gene, and some of the main pathological features include thoracic aortic 
aneurysm (TAA) progression. Losartan, an angiotensin II receptor blocker, has been shown to be 
successful in preventing aortic root dilation in mice, but failed to show any significant effects in 
human clinical trials. Thus, creating a TEBV using human MFS patient-derived SMC would be a 
better platform than animal models to model the MFS disease progression in vitro, and determine 
a more relevant drug-induced response of Losartan.  
This thesis aims to (i) successfully create a human cell-based TEBV system suitable for in 
vitro microphysiological system, and (ii) demonstrate the capability of the designed TEBV system 
in modeling a vascular disease for drug screening purposes. 
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1.2 Significance  
In vitro vascular model made up of tissue constructs, especially those comprised of human 
cells, can be of great use to observe and evaluate native vascular function in both normal and 
pathological conditions. Such biomimetic human-based analysis can be a significant step forward 
in the drug development research. Our current pre-clinical analysis for drug screening relies on 2D 
cell culture assays and animal models, and unfortunately the limitations of these systems cause 
major drawback towards successful production of drugs that can reach the commercial market. An 
accurate recapitulation of a drug-induced physiological response in a disease state can speed up 
the drug screening process with higher efficiency, and this will eventually increase the chances of 
successful treatment for patients. For this purpose, we designed and fabricated a small-diameter 
(1mm I.D.) TEBV using human cells capable of demonstrating vascular function.  
The second and third chapters of this thesis explore different cell sources and fabrication 
methods to optimize the TEBV fabrication process. First, MSC was explored as cell source for 
vascular wall for the ease of availability and its suitability in creating a cell sheet. However, a SMC 
source would be more advantageous, especially when modeling a vascular disease where SMC 
play a major role. In fact, because SMC and their phenotypic switching are integral to the 
regulation of vascular function, they naturally play a major role in the progression of various 
vascular diseases1. However, large quantities of SMC are necessary to create a tissue construct, 
and current SMC sources are in short supply2. While human induced pluripotent stem cells (iPSC) 
can be suggested as an alternative approach, they are dogged by issues of long derivation time, 
complex protocols involving an intermediate mesoderm stage, the possibility of remnant 
pluripotent cells, and overall maturity of differentiated cells3,4. The issues with iPSC can be 
potentially obviated through direct reprogramming. Here, myocardin (MYOCD) was 
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overexpressed in human endothelial progenitor cells (EPC) to directly reprogram them into 
functional SMC. While MYOCD has been well regarded as a master regulator for SMC 
differentiation5,6, no other group has shown that MYOCD alone can convert a non-muscle cell type 
into functional SMC. Our proposed approach would be the first to generate a SMC using direct 
reprogramming approach. This highly robust method of direct conversion is advantageous over 
iPSC-directed reprogramming in terms of efficiency and speed.  
The cell sheet design in our TEBV mimics that 3D spiral and interwoven organization 
shown in native blood vessels, and allows for a higher cell density than any scaffold-based 
construct can provide. While cell sheets can be an attractive method for TEBV fabrication, 
however, it takes at least 1 month to fabricate and depends solely on the cell’s ability to proliferate 
and secrete adequate amounts of extracellular matrix (ECM). Therefore, this is a time-consuming 
process that would not be suitable for high throughput in vitro drug screening system. Furthermore, 
cell sources that are not proliferative such as SMC cannot be used for cell sheet formation. Thus, 
dense hydrogel construct was explored as an alternative method that can be more fast and flexible 
in terms of their usage. The custom-built perfusion bioreactor used in this study allows for the 
maturation of TEBV under flow, which mimics the native microenvironment and further provides 
the biomechanical cues vascular cells are exposed to in the native state. In addition, our 
nondestructive imaging method that can monitor the TEBV response in situ provides an ease of 
analysis. 
So far only a limited number of studies have demonstrated the generation of alternative 
SMC from a patient source, and none using direct reprogramming7,8. Thus, in the fourth chapter 
of this thesis, we applied direct reprogramming to derive iSMC from MFS patient cell sources. As 
SMC play a key role in the progression of TAA in MFS9,10, the ability to understand and modulate 
 5 
SMC function would greatly enhance the development of effective therapeutic strategies for MFS. 
We further generated a TEBV construct using iSMCMFS to create an in vitro vascular model for 
MFS. Our TEBV construct is a better alternative to the current cell-based model8 by offering higher 
physiological relevance and deeper insights into MFS and TAA that cannot be depicted at a 2D 
cell culture level. In overall, our TEBV fabrication method, the direct reprogramming approach, 
and the custom-built perfusion system with appropriate biomechanical cues synergistically created 
a highly robust, patient-specific in vitro vascular model.  
 
1.3 Background 
1. In vitro microphysiological system. 
Establishing an appropriate ex vivo disease model and conducting effective drug 
screening studies are crucial steps in the development of therapeutic drugs11,12. Although an 
extensive in vitro cell-based assays and in vivo animal studies are required before any drug 
candidate reaches the clinical phase, many still fail to progress to commercialization, with an 
80% attrition rate for Phase I clinical trial drugs13. One major limitation of most pre-clinical 
studies is the failure to reproduce the human physiological conditions in vivo. In vitro cell-based 
assays do not account for the complex nature of the 3-D microenvironment in native tissues or 
organs that are crucial for many aspects of cell processes and function14,15. Many of the results 
from animal studies on the other hand cannot be extrapolated to humans due to cross-species 
discrepancy. In addition, constructing an animal model that displays a specific pathophysiology 
through surgery or transgenics requires a great deal of time and resources. As such, an alternative 
approach needs to be explored to advance the current drug development process. An emerging 
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trend is to create an in vitro microphysiological system with engineered tissue constructs 
comprised of human cells16-18. 
A blood vessel is an essential component of an in vitro microphysiological system19. 
Most of the integrated microphysiological system models established till date uses plastic 
channels to connect one tissue compartment to another. However, such design neglects the 
important role of blood vessels in both healthy and drug-administered state. Most drugs are 
administered intravenously, and are subsequently exposed to the functional endothelium in blood 
vessels. Thus, drug-induced vascular injury is an important part of the toxicological evaluation 
drug development, but this is often difficult to assess in animal models due to their mismatch 
with humans20,21. In addition, a functional vasculature is essential for proper gas and nutrient 
transport. A functional defect in a vasculature can lead to a progression of various diseases, to 
which many drugs under development are targeting22. Thus, fabricating a functional TEBV that 
can mimic the properties of a native human vessel is essential for creating a platform for 
effective drug screening in both healthy and diseases state.  
 
2. Development of Tissue Engineered Blood Vessels. 
The first landmark study by Weinberg and Bell in 1986 established the construction of 
completely biological TEBV created using bovine cells and collagen gel23. All three layers of the 
native vessel that is crucial for its proper function, adventitia consisting of fibroblasts, media 
consisting of SMC, and intima consisting of endothelial cells (EC), were present in the TEBV 
construct. However, the major limitation with this study, along with other early approaches, was 
that the construct lacked enough mechanical strength to be implantable. Therefore, to avoid such 
problem several groups have explored the usage of biodegradable scaffolds. Niklason et al. 
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created TEBV from bovine cells seeded in polyglycolic acid scaffolds and were able to maintain 
a 100% patency after 4 weeks of implantation in pigs24. However, a transition from animal cells 
to human cells for clinical application remained a major challenge. Poh et al. demonstrated that 
adult vascular cells isolated from elderly donors, who are the primary patient group for vascular 
substitutes, lack enough replicative capacity to be expanded into a mature vessel construct25. In 
particular, human SMC are difficult to acquire in a large number through current techniques 
involving biopsy and in vitro expansion due to their limited proliferation and quick senescence. 
Alternatively, L’Heureux et al. used scaffold-free self-assembled cell sheet approach to create a 
completely biological human cell-based TEBV consisting of all three human vascular cell 
layers26. These TEBVs met the mechanical strength required for grafting, such as burst pressure 
and suturability, and when implanted in an animal model for 7 days it could withstand 
physiological flow conditions26. However, L’Heureux and his colleagues faced the same issue of 
SMC senescence that decreased vessel mechanical strength, which is necessary for long-term 
implantation27.  
In efforts to eliminate this major hurdle, many groups including Niklason group and 
L’Heuruex group removed the medial layer containing SMC and developed a TEBV in vivo 
through an implanted acellular graft derived from decellularized blood vessels27,28. However, 
SMC play a fundamental role in regulating the vascular function. SMC display a unique 
plasticity in modulating from a contractile to a synthetic phenotype in response to various 
stimuli, and this plays a major role in vascular contraction, regulation of vessel tone and blood 
pressure, as well as maintenance of a functional endothelium29. Furthermore, SMCs secret 
elastin, a major ECM component in the medial layer that comprises 30-50% dry-weight of native 
vascular tissues30. Elastin plays an important role in supporting the compliance of vessel in 
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response to biomechanical stimuli as well as modulating signaling pathways associated with 
vascular function30-32. Although fibroblasts are shown to produce microfibrils, they are less 
capable of producing mature elastin when compared to SMC. In fact, most studies that report 
elastin deposition in TEBV have incorporated SMC33. Therefore, the exclusion of a SMC layer 
due to lack of resource creates a significant limitation in the biological and biomechanical 
properties of the TEBV. In order to include SMC as a major component of the TEBV, an 
alternate SMC source that can provide enough quantity for TEBV generation needs to be 
developed.  
 
3. Obtaining an alternative cell source: iPSC and Direct Reprogramming. 
The generation of iPSC through defined reprogramming factors opened a new era for 
regenerative medicine applications. The essential feature of iPSC technology that contributed to 
its Nobel Prize award only after 6 years of its discovery is the ability to manipulate the cellular 
fate of a terminally differentiated cell. Any easily accessible somatic cell source can be reverted 
to pluripotency through the delivery of reprogramming factors, and this generated iPSC then can 
be differentiated into any cell type. This allows for any type of cell, especially cells that are 
difficult to be isolated and expanded, to be derived and made largely available for various 
therapies such as tissue repair or replacement. Furthermore, iPSC are advantageous over 
embryonic stem cells (ESC) as it poses no ethical concerns and can be autologous. iPSC 
reprogramming was first introduced using viral vector-based delivery of defined transcription 
factors. Soon after, various non-integrating delivery methods such as episomal DNA and Sendai 
virus have been developed for clinical applications. Although at a low reprogramming efficiency 
compared to viral delivery, non-integrative methods ensure better safety by avoiding 
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complications such as tumorigenesis or random genomic integration. Current efforts with iPSC 
research are focused on disease modeling and regenerative medicine applications. Examples 
include deriving neuronal cells for the treatment of neurodegenerative disorders or spinal cord 
injury, retinal cells for macular degeneration, and cardiac cells for the treatment of heart diseases 
such as myocardial infarction. iPSC have also been applied for modeling and treating systemic 
diseases. However, iPSC reprogramming can be time-consuming, and to obtain the target cell 
type, multiple differentiation procedures are involved, followed by an extensive purification 
from residual iPSC and non-specific iPSC-derived cell lineages.  
Alternatively, the discovery that a set of defined transcription factors can guide cell fate 
to iPSC led to investigation of other specific transcription factors that can directly convert a 
somatic cell into another type of somatic cell. This direct conversion process is termed direct 
reprogramming, and is faster and potentially more efficient as it eliminates the need of going 
through an intermediate pluripotent state. Other advantages of direct reprogramming over iPSC 
include its possibility of in situ reprogramming, which has tremendous potential in regenerative 
medicine, and its ability to better recapitulate age-dependent diseases. Direct reprogramming was 
first demonstrated through the direct conversion of mouse embryonic fibroblasts to neurons and 
cardiomyocytes. Soon after the direct reprogramming approach was also verified using human 
cell sources. Currently, direct reprogramming has been utilized to derive various other cell types 
such as hepatocytes, endothelial cells, and myoblasts. Current limitations of direct 
reprogramming include the technology being still at an early stage with a lot of unclear 
mechanisms, and the lack of proliferation and low conversion efficiency remains the largest 
barrier towards its usage for regenerative medicine till date. 
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Chapter 2. Exploring different cell sources to optimize the 
configuration of human cell-based TEBV. 
2.1 Abstract 
The lack of proliferation and availability of native SMC create difficulty in using these 
cells as vascular wall source for TEBV. As an alternative, we first explored MSC as a cell source 
and fabricated aligned cell sheet that was capable of generating a scaffold-free TEBV construct. 
Nanopatterned PDMS, hypoxic environment and cell culture conditions including ascorbic acid 
was used to create a stand-alone MSC cell sheet structure. In the second part of this chapter, 
reasoning that SMC is an irreplaceable cell source especially for disease modeling, we used 
direct reprogramming approach to obtain an alternative SMC source. The direct conversion of 
human endothelial progenitor cells (EPC) to induced smooth muscle cells (iSMC) was 
demonstrated by the induced expression of MYOCD. The EPC undergo a cytoskeletal 
rearrangement resembling that of mesenchymal cells within 3 days post initiation of MYOCD 
expression. By day 7, the reprogrammed cells show upregulation of smooth muscle markers 
ACTA2, MYH11, and TAGLN by qRT-PCR and ACTA2 and MYH11 expression by 
immunofluorescence. By two weeks, they resemble umbilical artery SMC in microarray gene 
expression analysis. The iSMC, in contrast to EPC control, show calcium transients in response 
to phenylephrine stimulation and a contractility an order of magnitude higher than that of EPC as 
determined by traction force microscopy.  
 
2.2 Introduction 
An important consideration for creating a suitable human cell-based TEBV is the cell 
source. After all, cells are what makes up a tissue construct, and the cellular function together as 
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a whole is what makes up the tissue function. General cell properties such as proliferation and 
the ability to secrete ECM is important to maintain a mechanically robust and structurally 
integral tissue construct for a long term. In addition, the cell source must be readily available in 
large quantities in order to generate a tissue construct. More specifically, in case of blood vessel, 
the vascular cells must be able to contract and relax appropriately in response to stimuli, and this 
creates the vessel contraction and dilation that is essential for maintaining the vessel tone and 
blood pressure. 
In the native blood vessels, the medial layer of blood vessel is comprised by the non-
striated muscle cells called vascular SMC34. They are distinct from other muscle cell types such 
as cardiac or skeletal myocytes in terms of their ability to regulate their phenotype from 
contractile to synthetic depending on the environmental stimuli29,35. In a healthy state, SMC in 
the vasculature remain in their contractile phenotype, which is distinguished by the lack of cell 
proliferation and migration36,37. However, during post-vascular injury or progression of a 
vascular disease, vascular SMC switch to a synthetic phenotype, which is characterized by an 
increase in cell proliferation and migration, and a decrease in the expression of genes that control 
vascular contraction38,39. SMC thus uses their phenotypic plasticity to regulate major vascular 
functions such as contraction, vessel tone and blood pressure, and cross-talk with the functional 
endothelium. As such, SMC are an essential cell source for understanding vascular cell function 
in both healthy and diseased state, and thus are crucial component when designing a TEBV for in 
vitro pre-clinical studies.  
Unfortunately, obtaining an adequate amount of SMC source for tissue engineering 
applications have proven to be difficult. Only a limited number of cells can be obtained through 
biopsy, and in vitro expansion is impractical due to the low proliferation rate and quick 
 12 
senescence acquisition of SMC40. Thus, in the first part of this study, we explored if any 
alternative cell type could be used to create the vascular wall of TEBV.  
Based on previous studies, human MSC was demonstrated to be an attractive model cell 
source for creating a TEBV. MSC are readily available from various sources, and they are highly 
proliferative. They are also attractive cell sources for vascular tissue engineering based on their 
unique antithrombogenic properties, immune response modulation abilities, and multipotency for 
differentiation into vascular phenotypes41. While MSC do not normally differentiate into SMC 
phenotypes, culturing MSC together with EC promotes the MSC differentiation towards a more 
contractile phenotype, which can be further enhanced by the exposure to flow 42,43.  
Furthermore, previous studies have shown that culturing the MSC in a hypoxic 
environment (2% O2) and with the addition of L-ascorbic acid helps sustain MSC viability and 
multipotency and increase the production of collagen ECM, respectively22. These conditions can 
facilitate the formation of a uniform and confluent MSC cell sheet. Culturing cell sheets on a 
nanopatterned surface allows for the pre-alignment of the cells. This is particularly advantageous 
when constructing a TEBV since the layers in the native blood vessel are specifically aligned. 
The medial SMC layer is circumferentially aligned, while the luminal EC layer is longitudinally 
aligned to the vessel. This configuration is important for the functional and mechanical 
properties of the blood vessel. The pre-alignment of cell sheet can also mimic the 3-D spiral and 
interwoven organization that exists in the vessel medial layer. Therefore, in the first part of this 
study, we use MSC and create an aligned cell sheet using nanopatterened PDMS to be used as a 
TEBV vascular wall.  
However, in many vascular diseases, SMC play a fundamental role in the disease 
progression due to their unique cell properties. Thus, in case of disease modeling, it is more 
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suitable to use SMC over other cell types to make a TEBV. As an alternative method to obtain 
SMC than biopsy and in vitro cell expansion, previous studies have derived iPSC and 
subsequently differentiated them into SMC lineage40,44. While successful, this approach requires 
multiple differentiation steps as well as purification from residual iPSC and alternate iPSC-
derived cell lineages. On the other hand, direct reprogramming refers to a regulator-mediated cell 
conversion process involving a terminally differentiated cell being reprogrammed into another 
type of a terminally differentiated cell. This process eliminates the need of going through an 
intermediate pluripotent state, and therefore it is a faster and potentially more efficient method 
than the iPSC approach45,46. Direct reprogramming has already generated many different types of 
cells and thus has desirable implications for use with SMC45,47.  
For direct reprogramming to be practical for tissue engineering purposes, the starting cell 
type should be easily obtainable and highly proliferative. Human EPC, which can be derived 
from various blood sources including umbilical cord blood or peripheral blood, is an excellent 
starting cell source48. Blood can be easily extracted from patients, and the procedure for isolating 
EPC from whole blood sample is already well established in previous studies49. The in vitro 
expansion of EPC can be fast and efficient due to their high proliferation rate and the ability to 
maintain their endothelial phenotype even after multiple rounds of replication. Furthermore, 
because SMC and EPC make up the basic structure of the blood vessel, the usage of EPC for 
direct reprogramming to SMC is particularly ideal for generating an autologous TEBV for 
patient-specific, pre-clinical screening. In addition, iPSC and dermal fibroblasts are excellent 
starting cell source that are also easily obtainable and highly proliferative. Furthermore, 
biorepositories that offer wide range of patient sources mainly store iPSC and dermal fibroblasts 
as samples, which increases the practicality of their use.    
 14 
The direct reprogramming approach to generate SMC can be induced using MYOCD, a 
master regulator of smooth muscle gene expression5. MYOCD is a strong transcriptional co-
activator involved in the activation of cardiac and smooth muscle related genes through its 
interaction with the serum response factor (SRF). Previous studies have reported the role of 
MYOCD in regulating SMC development and differentiation50-52. Wang et al. demonstrated the 
activation of smooth muscle specific genes in non-muscle cells when MYOCD was expressed5. 
Li et al. reported that while MYOCD deficient mutant embryos form proper cardiac 
development, they die by day 10.5 due to complete absence of vascular SMC53. In addition, Du 
et al. indicated that MYOCD expression is developmentally regulated in visceral and vascular 
SMC during embryonic development, and the forced expression of MYOCD in undifferentiated 
mouse embryonic stem cells induces the expression of SMC-specific genes such as SM22α6. 
In the second part of this study, we demonstrate that a single transcriptional co-activator 
is sufficient to induce efficiently and quickly the direct transdifferentiation of human EPC into 
induced smooth muscle cells (iSMC). We generated iSMC using a lentiviral gene delivery 
system allowing the inducible expression of MYOCD in EPC. Using immunofluorescence, flow 
cytometry, and microarray gene expression analysis we confirmed the phenotypic conversion of 
iSMC from the EPC controls. We also measured the calcium signaling activity and cell traction 
force to evaluate their functional phenotypic characteristics.  
 
2.3 Materials and methods 
1. Cell culture methods. 
Bone marrow–derived human MSC were generously provided by Darwin J. Prockop of 
Texas A&M Institute for Regenerative Medicine. MSC below passage 5 were seeded at 5,000 
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cells/cm2 on collagen-coated, nanopatterned PDMS substrates and cultured using complete cell 
sheet media [α-minimum essential medium (Gibco) with 20% fetal bovine serum (Atlanta 
Biologicals), 1% penicillin/streptomycin (Life Technologies), and 82.5µg/ml L-Ascorbic acid 
(Sigma-Aldrich)] at 37 °C in a hypoxic chamber of 2% O2 for 3 weeks.  
Umbilical cord blood was obtained from the Carolina Cord Blood Bank and all patient 
identifiers were removed prior to receipt. The protocol for the collection and the use of human 
blood for this study was previously approved by the Duke University Institutional Review Board. 
Human umbilical cord blood derived EPC were derived as previously described49,54. EPC and 
iSMC were cultured in the complete endothelial cell growth medium (EGM) containing EBM-2 
(Lonza), EGM-2 supplement (Lonza), 10% fetal bovine serum (FBS, Atlanta Biologicals) and 
1% antibiotic / antimycotic solution (Life Technologies). Media was changed every other day.  
Human umbilical artery smooth muscle cells (UASMC, Lonza) were maintained in 
DMEM-LG (Sigma), supplemented with 3% FBS (Atlanta Biologicals) and 100U/ml 
Penicillin/Streptomycin (Life Technologies). 2µg/ml doxycycline (Sigma) was added to the 
culture medium for the inducing transgenic MYOCD expression. The culture medium was 
changed every two days for all culture conditions except during lentiviral transduction when the 
medium was changed after 24 hours.  
TEBV with MSC cell sheet and EPC were cultured in the complete cell sheet media. 
Media was changed every 5-7 days. TEBV with dense collagen gel were cultured in the complete 
EGM media. Media was changed every 2 days.  
 
2. Fabrication and characterization of PDMS nanopatterned substrates and aligned MSC sheets. 
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PDMS substrates with nanogratings of 350 nm line width, 700 nm pitch, and 250 nm 
depth were used for generating pre-aligned MSC sheets. Briefly, the nanopattern was fabricated 
on the poly(methyl methacrylate)-coated Si wafer by using electron beam lithography and then 
replicated on PDMS (Ellsworth Adhesives) using soft lithography. To create multiple copies of 
PDMS substrates, the original PDMS substrate was imprinted onto polystyrene (PS) disks under 
molding conditions of 210°C and 50 kPa for 5 min, followed by cooling to room temperature. A 
mixture of PDMS resin and curing agent (SYLGARD 184 kit, Dow Corning) was poured onto 
the nanograted PS mold (L= 6 cm, W= 4.5 cm) and cured for 2 h at 65°C. Before culturing MSC 
on the PDMS substrates, the substrates were oxygen-plasma treated with a Trion Phantom II 
Reactive Ion Etcher for 60 s, 300 mTorr chamber pressure, 20 cm3 O2 flow rate, and 20 W RF 
power. Plasma-treated substrates were immediately immersed in sterile EtOH for sterilization, 
and then coated with bovine collagen I (Sigma-Aldrich) at 15 mg/cm2 for 1 h to facilitate MSC 
attachment55-57.  
The pattern transfer fidelity from mold to replica and cell alignment onto the PDMS 
substrates were examined using scanning electron microscopy (SEM) (FEI XL30 SEM-FEG). 
Samples, either only the PDMS substrate or the PDMS substrate with MSC seeded, were fixed, 
dehydrated and dried, and then coated with a 10 nm layer of gold film (Denton Desk IV vacuum 
sputter coater) to improve sample conductivity for SEM imaging. 
 
3. MYOCD plasmid construction and lentivirus preparation.  
DNA plasmid vectors were prepared as previously described58. Briefly the MYOCD DNA 
vector (NCBI NM_001146312.2) was designed to produce lentiviral particles that allows the 
inducible expression of the protein molecule. For cloning, a lentiviral vector that controls the 
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expression of OCT459 (Addgene, 19778) was processed to remove the OCT4 gene and replace it 
with MYOCD (cDNA clone from BC126307, MHS4426-99239581, Open Biosystems).  
The lentivirus was produced as previously described58. Briefly, a second-generation 
lentivirus production system utilizing the psPAX2 (Addgene, 12660) and pMD2.G (Addgene, 
12559) vectors were used. HEK293T at 90% confluency in T-75 culture flask (pre-coated with 
0.1% gelatin (Sigma)) were transfected using Lipofectamine 2000 (Life Technologies) with a 
total of 24µg of the three lentiviral vectors (12µg expression vector, 7.7µg of psPAX2 and 4.3µg 
of pMD2.G) in Opti-MEM® (Life Technologies). The supernatant containing the viral particles 
was collected at 48 and 96 hours following initial transfection with a final volume of 20 ml. The 
supernatant was subsequently concentrated to a final volume of approximately 300 µl using 
Amicon Ultra-15 centrifugal filter unites (Millipore) and stored at 4°C for immediate use or in 
small aliquots at −80°C for long term use. To transduce EPC, the cells were plated at a density of 
approximately 10,000 cells/cm2 is 6-well plates. The next day 2ml of growth medium containing 
5µl of each viral concentrate (FUW.M2rtTA, FU.tet.on.MYOCD) and 8µg/ml polybrene 
(Sigma) was used to transduce the cells.  
 
4. Characterization of the iSMC phenotype. 
Fluorescent cell imaging was performed on either a Nikon Eclipse TE2000-U, a Zeiss 
510 inverted confocal microscope, or an Olympus IX51 inverted fluorescent microscope. 
Primary antibodies used included: anti-MYOCD (Santa Cruz, sc-21561), anti-Vimentin (Sigma, 
C9080), anti-TAGLN (Abcam, ab14106), anti-MYH11 (Abcam, ab683), anti-ACTA2 (Abcam, 
ab7817), anti-VWF (Abcam, ab6994), anti-CD31 (Life Technologies, 37-0700). Secondary 
antibodies used were raised in either chicken or goat against mouse or rabbit antibodies, and 
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conjugated to Alexa Fluor® 568 (red), Alexa Fluor® 488 (green), or Alexa Fluor® 350 (blue). 
Cell nuclei were detected using DAPI (Life Technologies). The actin cytoskeleton was stained 
and imaged using phalloidin conjugated to an Alexa Fluor® 488 (Life Technologies). Cells were 
fixed using paraformaldehyde (2% in PBS, Electron Microscopy Sciences) and permeabilized 
using Triton X-100 (0.2% in PBS, Sigma). Blocking solution included FBS (10%). Flow 
cytometry analysis was performed on a FACSCanto flow cytometer (Duke Core Facility, BD 
Biosciences). Antibodies used were: CD105-APC (Biolegend, 323207), CD31-APC (Biolegend, 
303115), Mouse IgG1,k Isotype control-APC (Biolegend, 400119). Meta-analysis of acquired 
data was performed using Cyflogic (www.cyflogic.com) and Microsoft Excel.  
For gene expression analysis, primers were designed using NCBI primer-BLAST. Total 
RNA was collected using the RNeasy Mini Kit (Qiagen). Quantitative RT.PCR analysis was 
performed on an 7900HT real time thermocycler using the QuantiTect SYBR Green one-step 
RT.PCR kit (Qiagen, 204243). The SDS software (ABI, version 1.4 or 2.4) was used to analyze 
the raw data, and additional analysis was performed on Microsoft Excel. Relative quantification 
was performed using the ΔΔCt method and statistical significance was determined using the t-
Test. The primers used for this experiment are the following:  
MYOCD_Fw: CAAGCCAAAGGTGAAGAAGC, MYOCD_Rv: 
TAGCTGAATCGGTGTTGCTG,  
CD31_Fw: CCAAGCCCGAACTGGAATCT, CD31_Rv: CACTGTCCGACTTTGAGGCT,  
CDH5_Fw: ATGCGGCTAGGCATAGCATT, CDH5_Rv: TTTCCTGTGGGGGTTCCAGT,  
ACTA2_Fw: GCCAAGCACTGTCAGGAATC, ACTA2_Rv: GTCACCCACGTAGCTGTCTT,  
MYH11_Fw: AGTATCACGGGAGAGCTGGA, MYH11_Rv: ATGTCCTCTCGTCTCTGGCT,  
TAGLN_Fw: GTCTTCACTCCTTCCTGCGA, TAGLN_Rv: CTTGCTCAGAATCACGCCAT,  
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ACTB_Fw: ACAGAGCCTCGCCTTTGCCGAT, ACTB_Rv: 
CATGCCCACCATCACGCCCTG.  
 
5. Microarray gene expression analysis.  
EPC were seeded at a density of 20,000 cells/cm2 and transduced with MYOCD as 
described in methods section 2.2.3. Control cell groups (EPC or UASMC) were also seeded at 
20,000 cells/cm2. 2 weeks post initiation of EPC direct reprogramming, cells were enzymatically 
dissociated and 1x106 cells from each sample were used for flow cytometry. Total RNA was 
collected from the remaining of dissociated cells (RNeasy Mini, Qiagen) for iSMC, EPC, 
UASMC (n=3). This was repeated for iSMC at the 4-week time-point (n=3). One week post 
initiation of transdifferentiation the culture medium used to maintain the derived iSMC was 
switched to SmBM (supplemented with SmGM-2, Lonza) and kept the same for the remainder of 
the experiment. Doxycycline was added to the iSMC culture medium only for the initial 2 weeks.  
Cells collected for flow cytometry analysis were incubated with anti-CD31 (PE conjugated, BD 
PharmingenTM) and anti-CD105 (APC conjugated, BD PharmingenTM) antibodies according to 
the manufacturer’s protocol. The control baseline for the analysis was established using cells 
which were pre-incubated with mouse IgG1,k isotype control (conjugated to either PE or APC). 
Analysis was performed using a FACSCanto II and the FACSDiva software package (BD 
Biosciences).  
Total RNA was assessed for quality with Agilent 2100 Bioanalyzer G2939A (Agilent 
Technologies) and Nanodrop 8000 spectrophotometer (Thermo Scientific). Hybridization targets 
were prepared with MessageAmp™ Premier RNA Amplification Kit (Applied Biosystems) from 
total RNA, hybridized to GeneChip® Human Genome U133A 2.0 arrays in Affymetrix  
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GeneChip® hybridization oven 645, washed in Affymetrix GeneChip®  Fluidics Station 450 and 
scanned with Affymetrix GeneChip® Scanner 7G according to standard Affymetrix GeneChip® 
Hybridization, Wash, and Stain protocols. (Affymetrix). This work was performed at the Duke 
University microarray core facility.  
Data analysis was performed as previously described58. Briefly, the Partek Genomics 
Suite raw data (CEL files) was imported and normalized using the RMA algorithm. 
Subsequently ANOVA statistical analysis was performed on the entire data set searching for 
significant differences between any one of the three groups (iSMC 2 weeks, iSMC 4 weeks, 
UASMC) and the negative control (EPC). Subsequently significantly upregulated or 
downregulated genes were identified based on the fact that p-value<0.05 and Fold Change< or 
>1.5. Hierarchical clustering analysis and principal component analysis were performed within 
the software suite itself. Derivation of the molecular pathway associated with smooth muscle 
contraction and based on the set of upregulated genes in the iSMC cell population was done 
using the GeneMANIA prediction server60. Principal component analysis was performed with 
additional control data files from previously published studies that were uploaded on NCBI Gene 
Expression Omnibus or EMBL-EBI Array Express: Skeletal Muscle (E-GEOD-31243, E-
GEOD-36297), Brain (E-TABM-1091), Liver (E-TABM-1091), Umbilical Vein and Coronary 
Artery Endothelial Cells (E-GEOD-10804), Aortic Smooth Muscle Cells (E-GEOD-29955, E-
GEOD-59671), Dermal Fibroblasts (E-GEOD-34309). Identification of molecular pathways 
associated with significantly upregulated or downregulated genes was performed using the 
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt)61. Data analysis for the identification of 
transcription factors associated with the same lists of genes was performed using PASTAA62. 
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6. Calcium transient activity.  
Human EPC were seeded into four 10-cm cell culture dishes at a density of 20,000 
cells/cm2 per plate.  24 hours post seeding, three of the four plates were transduced with a 
lentivirus allowing the constitutive overexpression of M2rtTA. 24 hours post-transduction, all 
plates were passaged into fifty 35mm plates at a density of 1x105 cells per plate: wild type / not 
transduced EPC (10 plates) and M2rtTA transduced EPC (40 plates). 24 hours post passaging, 
twenty of the M2rtTA transduced plates were also transduced with a lentivirus allowing the 
inducible overexpression of MYOCD. Induction of MYOCD expression was initiated 24 hours 
post transduction using 2µg/ml of doxycycline (Sigma). Five days post initiation of MYOCD 
overexpression all plates were transduced with a lentivirus allowing the overexpression of a 
genetically encoded calcium indicator (RGECO-1)63. Calcium imaging was first performed on 
day 10 post initiation of MYOCD overexpression. Moreover, the culture medium was switched 
to SmBM (Lonza) supplemented with SmGM-2 (Lonza) for half the plates of each condition and 
doxycycline was removed. Calcium imaging was also performed on day 17 day post initiation of 
MYOCD overexpression.  
For calcium transient detection, the 35mm plates were mounted onto a Nikon Eclipse 
TE2000 Inverted Microscope and maintained in an environmental chamber set to 37oC. Cells 
were incubated in 37oC Tyrode’s solution (135mM NaCl, 5.4mM KCl, 5mM HEPES, 5mM D-
Glucose, 0.33mM NaH2PO4, 1.8mM CaCl2 and 1mM MgCl2; pH 7.4 and 290mOsmol) during all 
imaging and stimulation steps. Cells in each plate were stimulated by direct addition of a drop of 
Tyrode’s solution (mechanical control), 50mM NaCl (negative control), 50-100mM KCl, 10 µM 
phenylephrine, and 100 µM phenylephrine, with an average of 50 seconds interval between each 
stimulus. For each plate, the intensity of the RGECO-1 fluorescence signal was recorded 
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following exposure to each stimulus and it was subsequently compiled into a single video file 
using the Nikon NIS Elements software.  
To determine the relative change in calcium concentration within the stimulated cells we 
analyzed the recorded video files using ImageJ. The area of selected responsive cells and the 
background was individually highlighted within each video file and the fluorescence intensity of 
the highlighted areas at each frame, represented by the ‘mean gray value’ parameter in ImageJ, 
were measured throughout the time course of the video. Initial background of all highlighted 
areas was averaged to determine the initial background fluorescence (F), and the fold change in 
fluorescence intensity was calculated for each cell by subtracting the intensity at each time point 
from the initial fluorescence (ΔF/F). RGB images were created using ImageJ to highlight peak 
fluorescence in concordance with fluorescent intensity graphs. 
 
7. Traction force microscopy.  
Polyacrylamide substrate was prepared with previously published protocols64,65. Confocal 
images and differential interference contrast (DIC) images were taken with an inverted Olympus 
FV1200 equipped with a live cell chamber and an UPLSAPO 20x (NA 0.75) objective. The DIC 
Images for EPC, UASMC and iSMC on elastic substrate, and the fluorescent beads on the top 
layer of elastic substrate were taken. The images for substrate without cell attachment (reference 
images) were taken after each experiment; in this case, cells were treated with Trypsin / EDTA 
(Life Technologies) for 30 minutes and allowed to completely detached from substrate.  
The displacement field was computed by comparing red fluorescent bead images 
obtained during the experiment with the reference image. The calculation was done by a Matlab 
program analysis using the method previously developed64,65. The traction field was calculated 
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from the displacement field. The total contraction force was calculated by addition of magnitude 
of traction force in each the filed all together. Color bars in displacement filed and traction field 




1. Generation of uniformly aligned MSC cell sheet using nanopatterned PDMS. 
The overall fabrication process for generating a scaffold-free TEBV is shown in Figure 1. 
MSC were seeded and expanded on nanopatterned PDMS mold (Figure 2A) under hypoxic (2% 
O2) conditions with 82.5µg/ml l-ascorbic acid for 3 weeks. The uniform alignment of MSC on 
the nanopatterned PDMS was observable in microscopic images (Figure 2B-C). Four layers of 
aligned cell sheets were then manually wrapped around a 1mm cylindrical mandrel (Figure 2D), 
and were matured for an addition of 2 weeks under the same culture conditions. The percentage 
of cell sheet shrinkage caused by the wrapping process was 16.7±3.2 % for n = 12. Because this 
measurement was consistent for every batch, the reproducibility of the TEBV fabrication was not 
affected. 
Immunofluorescence staining against actin filaments indicated MSC were confluent and 
uniformly aligned in the scaffold-free TEBV after 1 week of perfusion (Figure 2G-H). The SEM 
images of various TEBV sections (cross-section, longitudinal section of the lumen side, and 
longitudinal section of the outer wall) shows fused MSC cell sheet layers with confluent cell 





Figure 1. Overall experimental scheme of fabricating a MSC-based, scaffold-free TEBV. 
 
 
Figure 2. Images of aligned cell sheets and resulting TEBV. (A) SEM image of nanopatterned PDMS; 
(B, C) Phase images of aligned hMSCs grown on nanopatterned PDMS; (D) hMSC sheets wrapped 
around 1.3 mm diameter glass rod; (E, F) SEM images of circumferentially aligned hMSC in outer layer 
of TEBV; (G, H) Confocal images showing phalloidin staining (Red) and DAPI (Blue) of TEBV;  (I-L) 
SEM images of various TEBV sections demonstrating that the cell sheets were well fused to create 
multiple layers of the vessel wall with confluent cell density throughout the vessel from the lumen to the 
exterior (I: TEBV; J: longitudinal section showing lumen; K: longitudinal section showing the outer wall; 
and L: cross-section) 
	
2. Generation of induced Smooth Muscle Cells (iSMC) using direct reprogramming approach 
with human EPC. 
Human transcriptional co-activator MYOCD was transduced into primary human EPC 
using a second-generation lentivirus with a doxycycline (DOX)-inducible system (Figure 3A). 
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Following induction of MYOCD expression through the addition of doxycycline (DOX) we 
readily detected nuclear localization of MYOCD within 2 days post transduction as determined 
by immunofluorescence (Figure 3B). No MYOCD-positive nuclei were detected in the control 
cell population (M2rtTA only). Cell transduced with MYOCD underwent significant phenotypic 
changes within 4 days of DOX induction (Figure 3C). Endothelial-to-mesenchymal transition 
was evident in transduced cells as the original cobblestone-like shape (typical in EC) was 
converted into elongated and spindle-like shape often seen in SMC. Immunofluorescent staining 
against F-actin and vimentin over a period of time (2 days pre-induction, 3 days, and 7 days post-
induction of MYOCD expression) showed a gradual but significant cytoskeletal rearrangement, 
which also suggested a transition from an endothelial to a mesenchymal cytoskeletal phenotype 
(Figure 3D). 
While EPC transduction at higher virus titer was tested to ensure thorough transduction, 
this resulted in high cell toxicity and cell apoptosis within 7 days post-induction of MYOCD 
expression. Thus, only the low virus titer was used for the remainder of experiments. 
The expression levels of EC surface markers CD31 and CD105 on transduced cells 
undergoing direct conversion into iSMC were measured using flow cytometry (FACS) (Figure 
4A). While the control EPC was shown to be CD31 and CD105 double positive, transduced cells 
with 7 days of MYOCD expression induced a large and highly significant downregulation of 
both cell surface markers.  
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Figure 3. Direct reprogramming of endothelial progenitor cells into induced smooth muscle cells 
through the transient overexpression of MYOCD. (A) Illustration depicting the experimental design of 
our study. EPC were transduced with lentiviruses allowing the constitutive overexpression of a reverse 
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tetracycline-controlled transactivator (M2rtTA) and inducible overexpression of MYOCD through 
doxycycline (DOX). iSMC were characterized both morphologically and functionally. (B) Nuclear 
localization of MYOCD as shown by immunofluorescence staining against DAPI and MYOCD for EPC 
transduced with the M2rtTA and MYOCD following induction of expression via DOX exposure (right 
images), and control EPC transduced only with M2rtTA (left images). Nuclear protein expression was 
represented as either high (white arrows), low (red arrows), or absent (yellow arrows). (C) Phase contrast 
images showing the cell morphology for day 1 (top) and day 7 (bottom) following MYOCD expression 
via DOX exposure for EPC transduced with M2rtTA only, and low and high viral titers of MYOCD 
lentivirus. (D) Immunofluorescence staining against actin filaments and vimentin (intermediate filaments) 
for EPC transduced with MYOCD and M2rtTA for days -2, 3, and 5 post DOX induction.  
 
The relative expression levels of SMC and EC specific genes were measured via 
quantitative RT-PCR in the non-transduced EPC, EPC transduced only with M2rtTA, EPC 
transduced with a low virus titer of MYOCD, and EPC transduced with a high virus titer of 
MYOCD at day 7. MYOCD mRNA expression level was negligible and non-specific in the two 
control groups, while the levels were significantly upregulated (~150x and ~400x) in transduced 
groups relatively to the control EPC group (Figure 4B). Furthermore, the induction of MYOCD 
expression for 7 days was associated with a significant downregulation of EC markers CD31 and 
CDH5, and a significant upregulation of SMC markers ACTA2, MYH11, and TAGLN. This 
further supports our hypothesis that the transcriptional co-factor MYOCD alone can induce the 
direct reprogramming of EPC into iSMC. Although higher virus titer induced a higher expression 
levels of the three SMC genes than that of the lower titer, their long-term cytotoxic effect 
prohibited their further use. 
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Figure 4. Phenotypic characterization of iSMC. (A) The expression level of endothelial cell surface 
markers CD31 and CD105 in EPC and iSMC as determined by flow cytometry. (B) Gene expression 
analysis in control EPC (i), M2rtTA (ii), M2rtTA + MYOCDLow (iii), and M2rtTA + MYOCDHigh (iv) as 
determined by qRT-PCR for endothelial markers CD31 and CDH5, and smooth muscle markers ACTA2, 
MYH11, and TAGLN. (C) Protein expression analysis in control EPC, M2rtTA, and M2rtTA + MYOCD 
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as determined by immunofluorescence staining against smooth muscle proteins MYH11, ACTA2, and 
endothelial proteins CD31 and VWF.  
 
Immunofluorescence staining was performed against EC markers CD31 and vWF, and 
SMC markers TAGLN, MYH11 and ACTA2, and the corresponding expression levels (as 
determined by the fluorescence intensity) in the iSMC group were compared to that of the 
control groups (EPC only and EPC with M2rtTA only) (Figure 4C). MYH11 and ACTA2 
expression were readily detected in iSMC at high levels encompassing the entire cell area, while 
no significant expression was observed in the control EPC groups. Interestingly we detected 
TAGLN expression in both EPC and iSMC, although the protein was expressed at higher levels 
in iSMC and the expression was uniform within the entire cell area rather than being primarily 
around the cell borders (EPC). Compared to the CD31 and vWF double positive EPC groups, no 
vWF was detected on ACTA2 positive iSMC and no CD31 on TAGLN positive iSMC. Small 
colonies of EPC stained positive for either VWF or CD31 was detected within the iSMC 
cultures, indicating presence of cells that did not undergo direct reprogramming. These cells 
were also distinct in cell shape compared to the converted iSMC population.  
To assess the overall effect of the induced MYOCD expression on cells undergoing direct 
reprogramming to iSMC, microarray gene expression analysis was performed on iSMC 
following 2 weeks of continuous DOX-induced MYOCD expression (iSMC-2w) or 2 weeks of 
continuous DOX-induction followed by 2 weeks of standard culture without DOX (iSMC-4w). 
Control cells included non-transduced EPC and primary human smooth muscle cells isolated 
from the umbilical artery (UASMC). To ensure microarray analysis was conducted from solely 
reprogrammed iSMC population, cells negative for EC markers CD31 and CD105 were isolated 
using FACS prior to cell lysis and RNA isolation. The FACS analysis on control groups showed 
that approximately 98% of EPC were double positive for CD31 and CD105 as compared to only 
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0.03% of UASMC (UASMC were ~29% positive for CD105). iSMC at the 2 week time point 
were approximately 13% double positive for CD31 and CD105 whereas that percentage 
decreased to 0.35% at the 4 week time point.  
Plot of signal intensity ratios for individual chip probe when comparing each iSMC 
groups and UASMC to control EPC showed that each three groups exhibited variation in signal 
intensity for a number of probes (Figure 5A). Probes exhibiting a significant level of gene 
upregulation or downregulation (p-value: <0.05, fold change<or >1.5) were then selected (Figure 
5B), and 1239 commonly upregulated genes and 1823 commonly downregulated genes were 
identified from the three groups (Figure 5C). Hierarchical clustering analysis was performed on 
all probes exhibiting significant upregulation or downregulation in at least one of the cell groups 
that differed in their level of gene expression patterns (Figure 5D). In addition, pathway analysis 
was performed on groups of genes that are significantly upregulated or downregulated either 
specifically in iSMC as compared to EPC or iSMC and UASMC as compared to EPC (Figure 
5E). This analysis indicated that the upregulated genes were associated with pathways 
controlling smooth muscle differentiation and function as well as pathways controlling specific 
cell attachment to the extracellular matrix. On the other hand the downregulated genes were 
associated with pathways controlling various aspects of the cell cycle, suggesting that the cells 
exited the cell cycle, a finding that is consistent with what we observed in our cell cultures of 
iSMC. Importantly, a large array of genes associated with the smooth muscle contraction 




Figure 5. Microarray gene expression analysis performed on four cell populations. (A) Plot of signal 
intensity ratios for individual chip probe when comparing iSMC (2 weeks post induction of 
transdifferentiation, red), iSMC (4 weeks post induction of transdifferentiation, green), or control 
umbilical aorta smooth muscle cells (UASMC, blue) to control EPC. (B) Volcano plot displaying the 
relationship between the calculated fold change for individual chip probes versus the P-value as 
calculated using ANOVA statistical analysis (when comparing iSMC 2 weeks, iSMC 4 weeks, or 
UASMC to EPC). Plot includes probes that are significantly upregulated or downregulated (Fold Change 
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< or >1.5, P-value < 0.05). (C) Venn diagrams displaying the numbers of common or unique genes that 
are either significantly upregulated or significantly downregulated when comparing each of the three 
groups (iSMC 2 weeks, iSMC 4 weeks, UASMC) to control EPC. (D) Graphical representation of 
hierarchical clustering analysis performed on the union of all of the significantly upregulated (Red, +2.88) 
or significantly downregulated genes (Blue, −2.88). (E) Molecular pathways associated with significantly 
upregulated or downregulated genes when comparing only iSMC to control EPC as determined by the 
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt)61. The “Gene #” column refers to the number of 
identified genes that belong to a particular pathway and the “P-value” column refers to the P-value of 
each of the pathways and based on the number of identified genes. (F) A calculated smooth muscle 
contraction gene network based on known and predicted protein interactions (Co-expression, co-
localization, pathway, physical interactions, predicted interactions, share protein domains) as determined 
by the GeneMANIA prediction server60. Black circles mark genes that are significantly upregulated in 
iSMC (2 and 4 weeks) as compared to the control EPC. The table contains the level of gene upregulation 
and the P-value for each of the genes based on the ANOVA performed on all the data. Gray circles mark 
genes predicted to belong in the particular genetic network but found not to be significantly upregulated 
in iSMC as compared to EPC control cells. (G) Principal component analysis performed on the 
normalized signal values for each of the chip probes as well as probes from previously published studies: 
Skeletal Muscle66,67, Brain68, Liver68, Umbilical Vein and Coronary Artery Endothelial Cells69, Aortic 
Smooth Muscle Cells70,71, Dermal Fibroblasts72 
 
Finally, we performed a principal component analysis on the entire gene expression 
signature of our control and experimental samples (EPC, UASMC, iSMC) as well as control 
samples from previously published studies66-72. This analysis confirmed that the 
transdifferentiated iSMC closely resemble the control cells including adult aorta SMC and 
umbilical artery SMC while at the same time being significantly different from the starting EPC 
population (Figure 5G). 
The functional phenotype of iSMC was determined by monitoring the changes in 
intracellular calcium concentration to evaluate the cell contractile response. The calcium influx 
in cells in response to molecular stimulators was monitored in real time using a lentivirally-
delivered genetically encoded calcium indicator (R-GECO)63. The levels of calcium influx were 
determined by measuring the fluorescence intensity change over time and converting that to 
RGB images corresponding to the time at peak intensity for selected iSMC at 2 weeks and 4 
weeks post-induction of MYOCD expression as well as control EPC (Figure 6A-C). 
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No change in fluorescence intensity change was detected in all three cell groups when 
incubated in Tyrode’s solution. A small (100µl), local injection of 50mM potassium chloride 
(KCl), a chemical known to activate voltage-gated Ca2+ channels in SMC73, induced a small but 
significant increase in fluorescence intensity in iSMC at the 2 week time point (Figure 6A). 
Although a similar effect was not detected at the 4 week time point (Figure 6B), an increase in 
the concentration of KCl delivered (100µl, 100mM) readily induced a large and significant 
increase in fluorescence intensity. No change was observed in control EPC following the 
exposure to KCl (Figure 6C). Similarly, the addition of 100µM phenylephrine induced a steep 
transient increase of 75.6% and 117% in the fluorescence intensity in iSMC at both the 2 week 
and 4 week time point, but not in control EPC. 
iSMC contraction was also evaluated through traction force microscopy74,75. The traction 
forces produced by the cells were measured by analyzing the cell-mediated displacement of 
fluorescent beads within the hydrogel substrate. Color-coding was used to display the magnitude 
of bead displacement in iSMC at 4 week time point (Figure 6E) and control EPC (Figure 6D). 
iSMC at 4 week time point induced a significantly higher substrate deformation than did EPC. 
The calculated cell traction force of a single iSMC was approximately 10 times higher than that 




Figure 6. Functional characterization of iSMC using calcium transient mapping and cell traction 
force mapping. (A-C) Qualitative and quantitative output of calcium transient wave mapping in iSMC at 
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2 weeks post initiation of transdifferentiation (A), iSMC at 4 weeks after DOX removal (B), and control 
EPC at 4 weeks (C). RGB images (left) highlight cells of interest (numbered circles) at the peak change in 
fluorescent intensity (RGECO-1) outlined on the graphs (dotted box).  The graphs (right) show the change 
in calcium influx in the highlighted cells over time in response to the indicated substances as measured by 
the change in fluorescent intensity (RGECO-1) of the highlighted cells. The background fluorescence is 
labeled as (-). (D-E) Elastic substrate traction mapping of an iSMC (D) and a control EPC (E). Images on 
the left are phase contrast microscopy images, middle images are bead displacement maps, and images on 
the right are the calculated constrained traction maps, where color bars indicate relative values. (F) Total 
cell traction force generated by EPC (n=12), iSMC (n=10), and UASMC (n=10). Error bars represent the 
standard deviation. (# p<0.001, Student’s t-test). 
 
3. Using different starting cell sources for the generation of iSMC through direct reprogramming. 
Similar results were obtained when iPSC and fibroblasts were induced to over-express 
MYOCD using the lentiviral system (Figure 7). For iPSC, gene expression analysis using 
quantitative RT-PCR showed that SMC contractile markers CNN1, MYOCD, ACTA2, and 
MYH11 were significantly upregulated (Figure 7A), especially at a much higher level than that 
shown by the traditional growth factor treatment (PDGF-BB and TGFb) to induce SMC 
differentiation. Protein expression analysis using immunofluorescent staining against SMC 
contractile markers showed enhanced expression (Figure 7B). In particular, MYH11 protein, 
which was not expression in iPSC-SMC induced using just SMC differentiation media, was 
readily visible with MYOCD over-expression.  
 
Figure 7. Generation of contractile SMC from iPSC-SMC using MYOCD as an alternative for 
traditional growth factor treatment. Human iPSC from adult peripheral blood were induced into SMC 
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using SMC culture conditions as described previously76. (A) Gene expression analysis as determined by 
qRT-PCR for SMC markers, CNN1, MYOCD, ACTA2, and MyHC11. Undifferentiated iPSC was used 
as a negative control. Col I refer to the iPSC induced into SMC using just the culture conditions. Col I + 
PT refer to the iSMC differentiated into contractile SMC using growth factors PDGF-BB and TGF-B1. 
Col I + MYOCD refer to the iSMC differentiated using the MYOCD overexpression. (B) Protein 
expression analysis as determined by immunostaining against ACTA2, CNN1, and MyHC11.  
 
For adult human dermal fibroblasts (adHDF), MYOCD over-expression showed similar 
trend (shift towards SMC morphology, lack of proliferation, and upregulated SMC gene and 
protein expression) but at a higher viral titer (MOI 15). The starting cell type for deriving patient 
iSMC was chosen as dermal fibroblasts, because these were the most widely available cell type 
for most patient samples including MFS. Thus, the detailed experimental results involving the 
usage of these cell types are further described in chapter 4.  
 
2.5 Discussion 
Using nanopatterned PDMS, hypoxic environment and cell culture conditions containing 
ascorbic acid, we successfully created an aligned cell sheet using MSC. Notably, these cell 
sheets could be lifted from the surface to be rolled onto a mandrel and fused together to create a 
thicker layer. Creating such stand-alone structure without any scaffold demonstrates significant 
structural integrity, as shown by the immunostaining images against actin filaments and SEM 
images, and mechanical strength, which will be further discussed in chapter 3. Because such cell 
sheet formation relies solely on the cell’s ability to proliferate and produce enough ECM, the 
results from this study demonstrated the capability of MSC as a suitable cell source for 
generating a scaffold-free TEBV. Further assessment of MSC cell sheet as a suitable TEBV will 
be discussed in chapter 3.  
In the second part of this chapter, a robust approach involving the direct reprogramming 
of EPC to iSMC using induced expression of the human transcriptional co-activator MYOCD 
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was demonstrated. Activation of MYOCD expression induced quick phenotypic changes in the 
EPC cell population similar to those observed during the endothelial-to-mesenchymal transition. 
Concomitantly with the phenotypic changes, gene and protein expressions of iSMC 
demonstrated a downregulation of endothelial markers (CD31, CD105, CDH5) and significant 
upregulation of smooth muscle cell markers (ACTA2, MYH11, TAGLN). Using microarray 
gene expression analysis, it was shown that the derived iSMC activated pathways controlling 
smooth muscle cell differentiation, smooth muscle contractility, and specific attachment to the 
extracellular matrix, and at the same time deactivated pathways associated with cell cycling. 
Calcium imaging analysis indicated appropriate iSMC response when exposed to either KCl or a 
vasoconstrictor drug. Traction force microscopy measured a significant increase in the level of 
contraction force exerted by iSMC as compared to the control EPC.  
While using SMC as a cell source for TEBV would be advantageous as they are the 
major components of native blood vessels, native SMC are difficult cell source to access and 
have limited proliferation capacity. Our direct reprogramming approach provides an alternative 
SMC source and resolves this major drawback. In the past, several groups have also attempted to 
bypass this issue by deriving SMC-like cells from human embryonic stem cells (ESC) or human 
iPSC, which can be readily expanded in culture prior to their directed differentiation. In a first 
such report, Lee et al. described the generation of human iPSCs from human aortic vascular 
smooth muscle cells (HAVSMC) and their subsequent differentiation into smooth muscle cells 
via the formation of embryoid bodies77. The differentiated SMC had a similar morphology to that 
of the primary HAVSMC, expressed ACTA2, and showed a relative change in intracellular 
calcium concentrations in response to membrane depolarization exposure to a vasoconstrictor 
drug. More recently, Cheung et al. generated distinct vascular SMC subtypes by first 
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differentiating human ESCs or iPSCs into either neural crest, somite mesoderm, or lateral plate 
mesoderm and then inducing them to differentiate into SMC via the addition of TGF-b1 and 
PDGF-BB78. Importantly, their protocols allowed for a high differentiation efficiency and SMC 
purity, and the derived SMC were highly functional.  
A common denominator of the iPSC-directed differentiation into SMC is the prolonged 
process and issues with cell purity and safety. First the necessary derivation, expansion, and 
detailed characterization of the iPSC can take between 30 and 60 days. This is followed by an 
extensive differentiation protocol which in the best case scenario can last up to 20 days78. In 
addition, there is the requirement of ensuring purity of the SMC population as well as complete 
elimination of remaining undifferentiated cells (ESC or iPSC), which can cause teratoma 
formation if applied in vivo. On the other hand, the direct reprogramming approach established 
in this study has the advantages that 1) EPC can easily be obtained from various blood sources 
including umbilical cord blood or peripheral blood48,49; 2) EPC can proliferate rapidly while 
maintaining their endothelial phenotype; and 3) the direct reprogramming of EPC into iSMC is 
efficient and quick, taking as few as 14 days to acquire iSMC with phenotypic characteristics 
comparable to those of iPSC-SMC reported in the literature.  
An important finding of this work is the capacity of MYOCD to activate smooth muscle-
specific genes and ultimately induce the direct reprogramming of EPC into iSMC. The 
transcriptional co-activator MYOCD was first described by Wang et al. who used a 
bioinformatics-based in silico screen to identify cardiac-specific genes. They determined that 
MYOCD belongs to the SAP domain family of nuclear proteins and acts by associating with the 
serum response factor (SRF) to activate cardiac muscle specific genes79. In subsequent work the 
same group determined that MYOCD is a master regulator of smooth muscle gene expression 
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and can activate smooth muscle expression in various non-muscle cell types by associating with 
SRF5. In a more recent study it was reported that forced MYOCD expression in human ESC 
derived-embryoid bodies only selectively regulated CArG-dependent smooth muscle genes and 
allowed an increase in the number of SMC-like cells derived following one month of 
differentiation80. Altogether, these reports align with our findings that transient over-expression 
of MYOCD can convert EPC to SMC.  
A hallmark of smooth muscle cell function is its ability to contract in response to various 
vasoreactive drugs such as phenylephrine. This contractile response is regulated by transient 
receptor potential cation channels that control the intracellular levels of calcium and thereby 
regulate cell contractility81. In this study, the reprogrammed iSMC responded to phenylephrine in 
a similar manner to primary smooth muscle cells. Previous reports show that renal arterial 
smooth muscle cells initially respond with a sharp peak of calcium influx after addition of 10 µM 
phenylephrine and then a short plateau before returning to baseline82. This peak response is 
consistent with majority of the iSMC measured in this study with similar intensity levels, 
although a sustained plateau after the initial calcium influx was not observed. Furthermore, a 
higher concentration (100 mM) of KCl was needed to cause iSMC response at week-4 time point 
compared to that of week 2 (50 mM). Although this concentration is still within the range tested 
by previous studies73, this difference could have been resulted from the reduced levels of 
contractile protein expression caused by the removal of doxycycline induction after week 2, 
which is also confirmed by the microarray analysis. These results imply incomplete maturation 
or variation in the type of smooth muscle cell derived from the direct reprogramming method. 
The decrease in plateau presence in iSMC response between week 2 and week 4 may also allude 
to this maturation inconsistency as well as the need to apply higher concentrations of 
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phenylephrine (100 µM) in order to obtain such a response. Furthermore, studies with pulmonary 
aortic smooth muscle cells show a sharp peak in response to phenylephrine that oscillates over 
longer time periods83. Interestingly, oscillation of calcium transients was also observed in the 
iSMC throughout the cells as well as between cells, indicating potential cell-cell communication, 
which is important for the regulation of vascular tone84.  
Cells bind to ECM and other substrates through integrin clusters in the molecular 
structure called focal adhesions, which act upon actin-myosin bundles to exert cell contraction85. 
Importantly, the level of contractile force generated vary depending on the cell type, and the 
force amplitude closely correlates with particular cellular physiological functions requiring force 
generation, including contraction, adhesion, migration, and ECM reorganization85-87. Traction 
force microscopy analysis indicated that the contraction force of iSMC is significantly higher 
than that generated by control EPC, and comparable to that of native UASMC. As SMC are one 
of the major types of force-generating cells in human body, they generate much larger 
contraction forces than EPC. Thus, the significant increase in cell contraction force of iSMC 
demonstrates the functional change when compared to EPC, which could be attributed, but not 
limited, to an increase in ACTA2 level. Chen et al. previously reported that overexpression of 
ACTA2 in fibroblasts significantly increased the cell contraction force. Their findings suggest 
that ACTA2 expression correlates with cell traction force86. Here, iSMC showed elevated levels 
of ACTA2 expression (8x104 fold), accompanied by a significant increase in cell traction force 
(10 fold). This increase in contractility in iSMC is also comparable to that of iPSC-SMC, 
suggesting directly reprogrammed iSMC has similar maturity level as those differentiated from 
iPSC. Bajpai et al. previously reported that smooth muscle bundles made with Stage-3-
hiPSC (differentiated functional SMC) have a 12-fold increase in cell contractile force over those 
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made with Stage-2-hiPSC (immature stage), which shows a similar level of increase as observed 
in this study44.  
Overall, the direct reprogramming method of quickly deriving a large source of smooth 
muscle cells from an easily acquired cell source has opened many doors for the use of these cells 
in a variety of other applications, such as tissue engineering, gene editing, and disease modeling, 
that were not previously practical with primary smooth muscle cell sources.  
In terms of tissue engineering, iSMC have the potential to help fabricate multiple organ 
structures due to the broad presence of smooth muscle cells in the body, including, but not 
limited to gut, lung, esophagus, bladder, and blood vessels. Many of these structures are 
primarily composed of SMC and EPC. Therefore, both cell sources used in our method can be 
effectively applied for patient-specific studies of these engineered organs using a reduced 
number of primary cell sources, which tend to be much more difficult to acquire.  
In conclusion, we have demonstrated a fast method of generating SMC from human EPC 
through transdifferentiation using a single transcriptional activator: MYOCD. The derived iSMC 
display characteristics of SMC in terms of their phenotype and gene expression profile, and show 
functionality in terms of contractile response when exposed to appropriate vasoactive stimuli 




Chapter 3. Exploring different fabrication methods to generate 
TEBV with functional properties at normal physiological levels. 
 
3.1 Abstract 
 Creating TEBV that can achieve equally high levels of functional, biocompatible and 
mechanical properties can be difficult. As such, optimizing a fabrication method that is efficient 
and practical for in vitro disease modeling and drug screening is as essential as selecting the cell 
source. In this chapter, two different fabrication methods have been explored to generate a TEBV 
with functional properties at normal physiological levels. In the first method, hypothesizing that 
a scaffold-free TEBV may be advantageous, we constructed a tubular structure (1 mm I.D.) from 
aligned human mesenchymal cell sheets as the wall and human endothelial progenitor cell 
coating as the lumen. The burst pressure of the scaffold-free TEBV was above 200 mmHg after 
three weeks of sequential culture in a rotating wall bioreactor and perfusion at 6.8 dynes/cm2. 
The interwoven organization of the cell layers and extensive ECM formation of the scaffold-free 
TEBV resembled that of native blood vessels. The TEBV exhibited flow-mediated vasodilation, 
vasoconstriction after exposure to 1 µM phenylephrine and released nitric oxide in a manner 
similar to that of porcine femoral vein. Finally, HL-60 cells attached to the TEBV lumen after 
TNF-a activation to suggest a functional endothelium. Alternatively, we used dense collagen 
hydrogel and embedded directly reprogrammed iSMC to create a TEBV construct. The resulting 
iSMC TEBV showed appropriate functionality with respect to flow- and drug- mediated 





Most TEBV fabrication method involves building a cell-seeding scaffold with 
biomaterials such as synthetic polymers and hydrogels. However, despite extensive efforts, 
creating a TEBV using a scaffold material that can achieve equally high levels of functional, 
biocompatible and mechanical properties has been difficult88,89. Alternatively, groups such as 
L’Heureux et al. and Niklason et al. showed that a scaffold-free TEBV, comprised of cells and 
extracellular matrices (ECM) only without any synthetic or exogenous materials, could exhibit 
the desirable functional properties90,91. Furthermore, L’Heureux et al. validated the use of cell 
sheets to produce a functional TEBV with SMC and EC92. In these studies, the removal of 
exogenous and synthetic materials from the TEBV fabrication was presented as an advantage for 
vessel implant purposes, as synthetic materials may cause problems such as foreign body 
reaction or graft infection. While such issues are of lesser concern for in vitro systems, having a 
construct made up of just cells and ECM has a greater likelihood of achieving biological 
functionality similar to that of the native environment93,94. The cell sheet configuration also 
allows for a much higher cell density than those that include a scaffold. In fact, this is the same 
with the native blood vessel, which contains a highly dense SMC layer. 
In the first part of chapter 3, we fabricated a small-diameter (1 mm I.D.) TEBV 
comprising human MSC in the wall and human cord blood derived EPC on the luminal surface 
without any synthetic or exogenous materials. To mimic the 3D spiral and interwoven 
organization of SMC in native blood vessels, we prepared aligned MSC cell sheets on 
nanogratings and wrapped these cell sheets around a temporary supporting mandrel in a layer-
by-layer fashion. Maturation for 2 weeks and removal from the mandrel yielded a tubular 
structure with circumferentially aligned MSC. The lumen size of the tubular structure was 
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controlled by the diameter of the mandrel, 1 mm, and the wall thickness of the TEBVs was 
determined by the number of cell layers and maturation time. We characterized our scaffold-free 
TEBV and compared with those obtained from native porcine vessels. SEM analysis and 
immunofluorescent staining were used to visualize micro- and nanoscale features of TEBV and 
detect SMC, EC and extracellular matrix protein expression, respectively. The functionality of 
the TEBV was assessed by vasodilation and vasoconstriction in response to perfusion within the 
normal physiological range. In addition, the functionality of the endothelium was assessed with 
respect to nitric oxide (NO) release and monocyte adhesion. Finally, the mechanical strength was 
evaluated through burst pressure analysis.  
 To create a TEBV construct suitable for an efficient drug screening, an important factor 
to consider is that the system must be high throughput. In this aspect, the cell sheet fabrication 
might not be ideal as the fabrication time takes at least 5 weeks, and the cell sheet formation 
depends on the cell type’s ability to secret adequate amounts of ECM. Thus, to create a much 
faster and more versatile fabrication, an alternative method that will be discussed in the second 
part of chapter 3 is to use dense collagen hydrogel to make a TEBV construct. Cells dissolved in 
dense collagen solution are molded into a cylindrical construct with an inner diameter of 1 mm. 
By using plastic compression, a TEBV with reduced the water volume and increased collagen 
fiber density can be fabricated. This is a simple and efficient fabrication method that creates a 
perfusable TEBV in less than three hours, and thus has a significant advantage over other TEBV 





3.3 Materials and methods 
1. Fabrication of functional scaffold-free TEBV. 
To create a tubular vessel structure using MSC sheets, confluent MSC layers were 
carefully detached from the PDMS with tweezers and wrapped onto a temporary supporting 
mandrel (glass rod, 1 mm diameter). Four MSC sheets were rolled around a mandrel to form a 
TEBV, which were then stabilized in a complete media inside hypoxic chamber overnight to 
allow the cells to fuse together. For further maturation of the cellular assemblies, the cell sheets 
with the mandrel were cultured in a rotating wall bioreactor (Synthecon) at 37 °C in the hypoxic 
incubator of 2% O2 for 2 weeks. The temporary mandrel was then removed from the TEBV with 
tweezers, and the TEBV was inserted into a custom-built perfusion chamber (KISTECH, Korea).  
EPC (5×105 cells/vessel of 1 mm I.D. and 3 cm length) were seeded into the vessel by injection 
into the chamber using a 3mL syringe with Luer-LokTM Tip (BD Biosciences), and the chamber 
was rotated for 30 min with 0.17 rpm in the incubator to allow for an even attachment of EPC 
around the vessel lumen. The TEBV was then connected to a perfusion chamber running at a 
steady flow of 2 mL/min and further cultured for 2 weeks in 37°C and 5% CO243. The overall 
experimental scheme is shown in Figure 1.      
 
2. Characterization of scaffold-free TEBV. 
To examine the mechanical property of TEBV, burst pressure strength was measured. 
TEBV were mounted in a system custom-designed for pressurizing individual vessels until 
failure. TEBV were pressurized with water at increments of 300 mmHg in approximately 2 
minutes until rupture. 
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The biological activity of TEBV was evaluated after 14 days of culture in perfusion 
chambers. For each of the following stimuli-mediated responses, TEBV were recorded using a 
stereoscope (AmScope) and ISCapture software. To measure the response to flow-mediated 
dilation, TEBV were subjected to 0.5, 1, 2, and 4 mL/min flow rate for 2 minutes each. 
Screenshots of the recorded video were taken at each end-points to determine the change in 
vessel diameter. To measure the drug-mediated vasoconstriction, 1µM phenylephrine was added 
to the media and perfused for 5 minutes, and screenshots were taken before and after 
phenylephrine addition.  The diameter was calculated by averaging the measurements across the 
width of the vessel at 4 random spots over the entire vessel length using ImageJ. The 
vasoconstriction response to phenylephrine was measured as the percent change from the initial 
diameter to the diameter after 5 minutes. 
Media samples were collected to measure nitric oxide (NO) release. Media samples were 
frozen at -80°C and lyophilized (Appropriate Technical Resources) for 24 h. The lyophilized 
medium was resuspended into 1/10 of its original volume in double-distilled water (ddH2O), and 
mixed with equal volumes of 1X Greiss Reagent (Sigma) in a 96-well plate (BMG Labtech). 
After 15 min, spectrophotometric absorbance was measured at 540 nm. A standard curve was 
prepared using sodium nitrite solutions (Sigma) ranging from 0 to 80 µM in ddH2O. The values 
were analyzed by one-way analysis of variance (ANOVA), followed by nonparametric LSD 
tests. A p<0.05 was considered to indicate statistical significance. 
To observe the distribution of ECM and cellular alignment of matured vessels, 
immunofluorescence staining was performed. TEBV were fixed with 4% paraformaldehyde 
(Electron Microscopy Sciences) in PBS for 24 h at room temperature, and permeabilized in a 
blocking solution consisting of 0.03 g/ml bovine serum albumin (BSA, Sigma) and 0.1% goat 
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serum (Sigma) dissolved in 0.2% Triton X-100 (Sigma) diluted with PBS for 2 h. Primary 
antibodies used include: anti-PECAM (Abcam), anti-ACTA2 (Abcam), anti-type IV collagen 
(Abcam,) and anti-laminin (Abcam). Secondary antibodies were conjugated to Alexa Fluor® 568 
(red), Alexa Fluor® 488 (green). After the staining, the samples were mounted in Fluoro-Gel 
(Electron Microscopy Sciences) and viewed with a Zeiss LSM 510 inverted confocal 
microscope.  
To test the functionality of the endothelium in TEBV, monocytes adhesion onto the 
activated endothelium was measured. First, monocyte-like HL-60 cells (ATCC, CCL-240) were 
labeled with 2µM CMFDA (Molecular Probes) in culture medium for 30 minutes. The TEBV 
was labeled with 0.5µM DAPI (Molecular Probes) after fixation and permeabilization. For 
endothelial activation measurement, the TEBV was perfused with culture medium containing 
500U TNF-alpha for 4 hours, and then HL-60 cells (105 cells/mL) were perfused through the 
TEBV at a shear stress of 1.4 dynes (perfusion at 2 mL/min) for an additional 40 min. The TEBV 
was gently washed in medium without HL-60 cells three times and then fixed with 4% PFA in 
PBS. The TEBV was then cut open and imaged on the lumen side using a Zeiss LSM 510 
inverted confocal microscope. For HL-60 cell counting, the fluorescent images showing labeled 
HL-60 cells were analyzed using ImageJ software. 
 
3. Assembly and functional characterization of dense collagen TEBV.  
To create TEBV using dense collagen gel, 1.5X106 iSMC, resuspended in 300µl of 
SmBM supplemented with SmGM-2 (Lonza), were embedded in 2.05mg/ml of rat tail collagen 
type 1 solution (Corning) dissolved in 0.6% acetic acid. The solution was allowed to gel by 
raising the pH to 8.5 using NaOH, and incubated in the cell culture hood at room temperature for 
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30 minutes in a 3 mL syringe mold containing a 0.8 mm mandrel inserted through the middle. 
After gelation, the construct was placed on a 0.2 µm Whatman nylon membrane filter and 
subject to compression around the mandrel for 7-8 minutes to remove over 90% of the water. 
The collagen vessel construct was then slide off the mandrel and into a perfusion chamber where 
it was sutured at both ends to grips that allow for perfusion through the lumen of the vessel. EPC 
was seeded into the lumen as described in chapter 3, section 3.1. The chamber was then 
integrated into a continuous, steady, laminar perfusion circuit at a flow rate of 2 mL/min to 
ensure the application of physiological shear stresses of 6.8 dynes/cm2 to the vessel wall. The 
vessel was matured within the flow loop at 37°C for 7 days. The same procedure was followed to 
create the control vessel, but 1.5X106 EPC were embedded in the collagen construct in place of 
the iSMC. 
To determine the functionality of the vessels after 7 days of perfusion, the change in 
vessel diameter in response to gradual increase of flow rate, 1 µM phenylephrine and 1 µM 
acetylcholine were evaluated. The procedure for recording and measuring the vessel diameter 
change is described in chapter 3, section 3.2, with the addition of following procedure for 
acetylcholine measurement: After 5 minutes of 1µM phenylephrine perfusion, 1 µM 
acetylcholine was added to the media and perfusion was continued for another 5 minutes. 
Screenshots of the recorded video were taken at 30 seconds (before phenylephrine addition), 5 
minutes (after phenylephrine addition) and 10 minutes (after acetylcholine addition). The vessel 
diameter at each time point was calculated as previously stated. The vasodilation response to 
acetylcholine was measured as the percent change from the diameter after 5 minutes to the 
diameter after 10 minutes. 
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After the functional tests, vessels were taken out from the chamber and cut longitudinally to 
expose the vessel lumen. The flattened vessels were then fixed in 4% paraformaldehyde 
(Electron Microscopy Sciences) for subsequent immunofluorescence staining. 
 
3.4 Results 
1. Scaffold-free TEBV using MSC cell sheet and EPC 
After the cell sheets had fused and matured into a vessel form, the mandrel that acted as a 
temporary scaffold was removed. The outer diameter of the TEBV was 1.13±0.44 mm. The 
scaffold-free TEBV was then inserted into a custom-built perfusion bioreactor, and EPC were 
seeded into the TEBV lumen. Previous studies have shown that exposure to flow conditions 
increases the mechanical strength, contractility and SMC differentiation of a TEBV97,98. Thus, a 
continuous flow of 2 mL/min (physiological shear stress of 6.8 dynes/cm2) was set for the 
bioreactor for a week before any analysis was conducted. The burst pressure of the TEBV was 
measured with a custom-built pressure system pressurized with PBS solution inserted at one 
TEBV end. The measurements for our scaffold-TEBV were 342.3±101.2 mmHg, which is higher 
than that of human physiological vascular microenvironments (normally < 200 mmHg)99. This 
shows that our TEBV construct has a mechanical strength appropriate for mimicking native 
blood vessels. 
Immunofluorescent staining against ECM components in the basal lamina (collagen IV 
and laminin), SMC (α-smooth muscle actin), and EC (platelet endothelial cell adhesion molecule 
(PECAM)) markers were then analyzed and compared to the native blood vessel (Figure 8). The 
expression levels of each marker (as determined by fluorescent intensity) were increased in 
TEBV after the perfusion (from d0 to d7), and at d7 the levels were comparable to that of the 
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native vessel. The increased levels of collagen IV and laminin indicates that MSC in the TEBV 
wall secreted basal lamina ECM proteins that surround the smooth muscle layer. The high 
fluorescence intensity levels for SMC and EC markers demonstrates a MSC-to-SMC 
differentiation and the presence of a confluent endothelium, respectively.  
Further, the cell alignment in TEBV relative to the flow is indicated in the 
immunofluorescent staining images (Figure 8). MSC in the TEBV wall (indicated by the DAPI 
and ECM markers) had aligned perpendicular to the direction of flow in the bioreactor, while 
EPC had aligned parallel to the direction of flow. This observation is consistent with the 
corresponding staining images of the native vessel, and previous studies that indicate SMC tend 
to orient in a direction perpendicular to the blood flow100, while EC orient in a direction parallel 
to the blood flow101. Furthermore, Lee et.al reported that the perpendicular orientation of SMCs 
is important for the mechanical strength and the function of the blood vessels, and such 
alignment is regulated by the mechanotransduction mechanisms often observed when SMCs are 
subjected to high strain28. Thus, the perpendicular orientation of our MSC in the TEBV suggests 
that the MSC exhibit a SMC phenotype that allow for proper vascular function. 
The vascular function of the scaffold-free TEBV was assessed in terms of flow-mediated 
vasodilation, phenylephrine-induced vasoconstriction, and the corresponding nitric oxide (NO) 
release under each stimulus (Figure 9). Flow-mediated vasodilation is a noninvasive diagnosis 
for detecting endothelial dysfunction in systemic arteries, particularly for patients with risk of 
atherosclerosis or coronary artery disease102,103. Studies indicate that flow rate increase causes 
vasodilation by releasing endothelium-derived relaxing factor such as NO104, and this is 
dependent on an intact, functional endothelium105. To test vasodilation, the flow rate was 
gradually increased from 0.5 to 4 mL/min in double increments. Our results showed that the 
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vessel diameter increased as the flow rate increased, and the diameter change was large enough 
to be visually observable. The diameter change (% increase) measurements are shown in Figure 
9A. To test whether flow-mediated vasodilation indeed releases NO, the amount of NO released 
by the TEBV at each flow rate was measured. The results showed a similar trend as that of the 
vasodilation: the NO concentration increased with the increased flow rate. This agrees with 




Figure 8. Structural and functional characteristics of Scaffold-free TEBV. (A) Confocal images 
showing immunostaining for PECAM, SMA, Type IV collagen, and laminin of scaffold-free TEBV 
cultured for 7 days in the perfusion chamber and native porcine femoral vein, respectively. (B) 
Immunofluorescence staining images show that the MSC align perpendicular to the direction of flow in 
the bioreactor, which is consistent with previous report that smooth muscle cells tend to orient in a 
direction perpendicular to blood flow. (C) Monocyte adhesion assay shows the attachment of HL-60s 
(arrows) to the endothelial cells and beside the aligned smooth muscle cells in the TEBV. (D) Density of 
the attached HL-60 cells on the activated endothelium of TEBV. No attached HL-60 cells were observed 
if the TEBV was not endothelialized. Error bar indicates standard error. 
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Phenylephrine is a vasoconstrictor drug that acts as an α-adrenergic receptor agonist for 
vascular SMC. To test TEBV vasoconstriction, 1µM of phenylephrine was added to the 
perfusion bioreactor, and the results showed that the TEBV diameter was reduced by 4.8±0.3% 
(Figure 9B). The vasoconstriction level was not statistically different from that of the native 
porcine femoral vein under identical treatment (6.1±1.3%). Furthermore, the amount of NO 
released by the TEBV under the phenylephrine treatment was comparable to that released by 
native porcine femoral vein (p>0.05).  
 
Figure 9. Response of scaffold-free TEBVs to flow rate (A) and 1µM phenylephrine (B). The flow 
rate was gradually increased from 0.5 to 4 mL/min in doubling increments and the vessel diameter 
increased as the flow rate increased (*, p<0.05). The decrease of vessel diameter and the amount of NO 
release in response to the drug was comparable to those of native vessels (**, p>0.05). 
 
The presence of an intact, functional endothelium was validated through a monocyte 
adhesion assay. Inflammation is body’s nonspecific defense mechanism against tissue damage, 
irritant or pathogen, and the interaction between vascular endothelium and leukocytes is crucial 
for a complete inflammatory response to occur107. Following a pro-inflammatory stimulus, such 
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as drug-induced vascular injury, various cytokines, such as TNF-a, induce the upregulation of 
adhesion molecule expression on the surface of EC to initiate leukocyte binding and develop 
inflammatory responses108. To mimic such event in the TEBV, we added TNF-a to the perfusion, 
flow monocyte-like HL-60 cells on the activated endothelium, and observed cell adhesion in the 
TEBV. A strong attachment of HL-60 cells was observed on the activated endothelium of the 
TEBV even after 4 hours of continuous perfusion (Figure 8C). The image was taken with the 
lumen facing up, which indicated that the stained HL-60 attached to the EC and beside the 
aligned SMC in the TEBV. The density of attached HL-60 cells in various areas was measured 
and represented in Figure 8D, which shows that a relatively good uniformity of HL-60 cells were 
present throughout the endothelium. In contrast, monocyte adhesion was not observed in the 
control TEBV without the TNF-a treatment. 
 
2. Dense collagen hydrogel TEBV using iSMC and EPC 
A tubular collagen construct that mimics the basic structure of a small-diameter TEBV 
was fabricated using dense collagen hydrogel (Figure 10A). iSMC was embedded in a dense 
collagen gel to act as a vessel wall and EPC was seeded inside the construct to represent the 





Figure 10. Characterization of iSMC TEBV using dense collagen hydrogel. (A) Schematic of dense 
collagen hydrogel TEBV fabrication process. (B) Vasoactivity of EPC control and iSMC TEBV in 
response to the addition of vasoactive drugs, 1µM phenylephrine and acetylcholine, and increased flow 
rate from 0.5 mL/min to 4 mL/min. (C,E) Immunofluorescence staining against SMC markers ACTA2 
and CNN1 for (C) iSMC TEBV with low seeding density (1.5 million) and EPC control TEBV, and (E) 
iSMC TEBV with high seeding density (12 million) in both longitudinal section (left) and cross-section 
(right).  (D) Vasoactivity in response to addition of 1µM phenylephrine for iSMC TEBV with high 
seeding density (12 million), iSMC TEBV with low seeding density (1.5 million), nHDF TEBV, and 
MSC cell sheet TEBV.  
 
The vasoactive response of the collagen gel TEBV was measured in a similar manner as 
performed with scaffold-free TEBV (section 3.4.1). Flow-mediated vasodilation results showed 
that the TEBV with iSMC as the vessel wall dilated 6.37 ± 0.64% in response to increasing flow 
rate from 0.5 mL/min to 4 mL/min (Figure 10B). In contrast, the control TEBV with EPC only 
dilated at a significantly reduced level, which may be due to the expansion of the collagen 
construct. Thus, greater increase in the dilation of the iSMC TEBV can be attributed to the iSMC 
response to increasing flow rates, which also triggers endothelial production of NO. 
Drug-mediated vasoconstriction results showed that the iSMC TEBV constricted by 2.0 ± 
0.25% in response to 1µM phenylephrine, while the EPC TEBV showed minimal response 
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(Figure 10B). In addition, drug-mediated vasodilation was measured through the addition of 
1µM acetylcholine, a muscarinic receptor agonist against SMC and endothelial cells (EC). The 
change in the vessel diameter in response to acetylcholine was measured with the phenylephrine-
mediated constricted state as the initial time point. Results showed that iSMC TEBV dilated by 
1.9 ± 0.21% while the EPC TEBV responded by an insignificant amount.  
Immunofluorescent staining against SMC contractile proteins ACTA2 and calponin 
(CNN1) showed high levels of expression (as indicated by fluorescence intensity) in iSMC 
TEBV (Figure 10C). While EPC TEBV did show presence of ACTA2, there was no presence of 
CNN1, which is a more definitive marker for contractile SMC. Previous studies have indicated 
that ACTA2 is present in both EC and SMC. Both TEBV constructs stained positive for vWF, 
indicating the presence of an endothelium. 
Here, the initial cell seeding density for iSMC was set as 1.5 million cells based on 
studies with neonatal human dermal fibroblasts (nHDF) or MSC in collagen construct109. 
Because this density was optimized for nHDF and MSC, which have high proliferation rate, it 
was not an adequate amount for SMC TEBV to exhibit proper vasoactive response in 
comparison to when using nHDF or MSC TEBV. Native SMC in the vessel do not proliferate 
under normal physiological conditions, and thus our iSMC that recapitulate this phenotype show 
low proliferation in situ. Thus, to compensate for the low proliferation, the initial cell seeding 
density needs to be higher to show proper vascular function. From our preliminary studies, the 
maximum amount of cell number capable of being embedded in a collagen gel without 
disturbing the gelation process was approximately 12 million cells. This results in higher levels 
of vasoactivity in iSMC TEBV in comparison with NHDF TEBV at the same time point (Figure 
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10D), and maintain strong expression of SMC contractile proteins throughout the tissue sections 
(Figure 10E).  
 
3.5 Discussion 
In this chapter, two different fabrication methods to create a TEBV, the scaffold-free, cell 
sheet and dense collagen hydrogel, were demonstrated and various analysis were applied to 
assess whether the generated TEBV is functional at normal physiological levels.  
First, a scaffold-free TEBV made up of aligned MSC cell sheets and EPC was generated 
to mimic the native blood vessel. It is hypothesized that removing any exogenous and synthetic 
materials from the TEBV construction would achieve a greater likelihood acceptable 
functionality for drug screening93,94. In addition, a scaffold-free configuration holds the 
advantage of achieving a much higher cell density than that in a scaffold-based TEBV110. After 
all, a native blood vessel contains a highly dense SMC layer. Pre-aligning the cells in the cell 
sheet method may also approximate the 3D spiral and interwoven organization that exists in the 
medial layer of a native blood vessel.  
The cell sheet-based construction loses the ancillary mechanical support of a scaffold, 
which may be detrimental for in vivo applications. This concern is alleviated for drug testing in 
vitro. Nevertheless, the burst pressure obtained for the MSC cell sheet TEBV in this study is 
within range of that for native human vessel99. Moreover, the mechanical properties of the 
proposed TEBV can be improved by using more cell layers as well as a longer maturation time. 
However, such gain must be weighed against the materials and time needed to construct the 
TEBV. On balance, the protocol described in this study appears adequate to produce a construct 
reasonably functional within five weeks. 
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The functions of the TEBV were assessed in terms of flow-mediated vasodilation, 
phenylephrine-induced vasoconstriction, and the corresponding NO release under each stimulus. 
Flow-mediated vasodilation is a noninvasive diagnosis for detecting endothelial dysfunction in 
systemic arteries, particularly for patients with risk of atherosclerosis or coronary artery 
disease102,103. Studies indicate that an increase in flow rate causes dilation of vessels by releasing 
endothelium-derived relaxing factor such as NO104, and this dilation is dependent on an intact, 
functional endothelium105. In accordance with the previous findings, our results shown in Figure 
9 indicate that increase in flow rate causes an increase in both the vessel diameter and the NO 
release. This implies that our TEBV has a functional endothelium that modulates vessel tone in 
response to external stimuli such as flow rate. Indeed, the immunofluorescence staining for 
PECAM in TEBV indicates the presence of a confluent layer of endothelial cells in the vessel 
lumen (Figure 8). In addition, administration of 1 µM of phenylephrine, which acts on vascular 
smooth muscle cells to create vasoconstriction111, showed similar percentage decrease in the 
vessel diameter between the TEBV and the native porcine femoral vein (Figure 9). The level of 
NO release under phenylephrine treatment was also similar. Therefore, it suggests that the TEBV 
contains MSC that exhibit a contractile SMC phenotype. This was confirmed by the expression 
of a SMC marker, alpha-smooth muscle actin, in Figure 8. Furthermore, Lee et.al have studied 
the flow-stimulated perpendicular alignment of SMC in the vessel wall28. They stated that the 
perpendicular orientation of SMC is important for the mechanical strength and the function of 
the blood vessels, and such alignment is regulated by mechanotransduction mechanisms often 
observed when SMC are subjected to high strain28. Thus, the perpendicular orientation of our 
MSC in the TEBV (Figure 8B) suggests that MSC exhibit a SMC phenotype and allow for 
proper vascular function. 
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The monocyte adhesion assay further validated the presence of a functional endothelium 
in our TEBV. Inflammation is a crucial nonspecific defense against tissue damage, irritant or 
pathogen, and the interaction between vascular endothelium and leukocytes is necessary for a 
complete inflammatory response to develop107. Following injury or a pro-inflammatory stimulus, 
various cytokines, such as TNF-a, induce the up-regulation of adhesion molecule expression on 
the surface of endothelial cells to initiate the binding of leukocytes and develop inflammatory 
responses108. In this study, we observed the adhesion of monocyte-like HL-60 to the endothelial 
cells in the TNF-a-activated TEBV lumen, but not to the TEBV without endothelialization. This 
demonstrates that a functional endothelium is necessary for monocyte adhesion, and that our 
TEBV contains such mature endothelial layer.  
So far our TEBV has only been compared to the native animal vessel. Although the 
assessments demonstrate comparable functionality, there is a need for direct comparison with 
native human vessels under the same stimuli. In fact, the goal of our future studies is to test drug 
compounds that have shown poor correlation between pre-clinical studies and clinical trials, so 
as to validate the use of TEBV as a drug screening platform. In summary, this study is a first step 
towards the development of a human cell-based microphysiological system that incorporates 
drug exposure to an endothelium as an integral part of drug screening.  
The second TEBV fabrication method used dense collagen hydrogel as a scaffold. The 
generated iSMC TEBV displayed contractile SMC protein expression, and responded to the 
vasoactive drugs phenylephrine and acetylcholine, in contrast to the control EPC TEBV. These 
results are consistent with the literature that shows SMC contract in response to phenylephrine, 
and the addition of acetylcholine can recover this constricted state by stimulating the production 
of nitric oxide from the healthy endothelium to induce SMC relaxation112. In addition, our results 
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suggest that iSMC TEBV dilated in response to increased flow rate at much higher level than 
EPC TEBV. While EPC TEBV also dilated, this may be due to the expansion of the collagen 
construct in which the cells are embedded, and the greater increase in dilation seen from the 
iSMC TEBV can be attributed to the iSMC response to increasing flow rates, which also triggers 
endothelial production of nitric oxide. Altogether, these results highlight the functionality of the 
iSMC in a collagen hydrogel TEBV construct as well as the presence of a healthy endothelium.  
While drug-induced vascular injury can greatly influence the toxicological evaluation of 
drug candidates under development, the exact mechanisms that cause smooth muscle and 
endothelial cell injury have not been studied in detail. TEBV that mimic the medial layer of 
smooth muscle cells and a luminal layer of endothelial cells in small diameter blood vessels can 
be of great use to model such drug-induced vascular injury23.  
Previous generation of TEBV constructs have relied on the use of fibroblasts or MSC to 
mimic the medial layer, as SMC are difficult to isolate and expand in the quantity necessary for 
generating a tissue construct. Nevertheless these TEBV contain a functional endothelium, and 
have effectively simulated the cytokine triggered endothelial activation and the subsequent 
adhesion of inflammatory cells onto the endothelium113. A healthy functioning endothelium is 
critical for regulating the vascular tone and growth, and its dysfunction can lead to 
cardiovascular disease such as hypertension or coronary artery disease114. Thus, an 
endothelialized TEBV would be important for the accurate study of the mechanism involved in 
endothelial activation and related inflammatory process during vascular injury115. 
However, the medial layer in MSC and fibroblast TEBV constructs cannot accurately 
mimic the increased proliferation of SMC that occurs after vascular injury. This phenotype 
switching is unique to SMC and is closely associated with vascular diseases such as 
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atherosclerosis1. Furthermore, SMC-EC interaction plays a major role in maintaining such 
proliferative capacity of SMC and ultimately regulating the vascular tone. For instance, the 
endothelium produces vasoconstrictor substances that modulate the proliferation of SMC112. 
Therefore, SMC-EC interaction is important for establishing a functional endothelium. In this 
regard, previous TEBV designs have been limited by their cell source to accurately model injury 
to the vasculature in terms of smooth muscle and endothelial cells. Therefore, the usage of iSMC 
with EPCs for TEBV generation described in this study can serve as an attractive vascular injury 
model that overcomes previous limitations. iSMC TEBV have the potential to more accurately 
depict the disease phenotype and progression by incorporating the native cell type. Moreover, 
our iSMC express the contractile phenotype after derivation, which is evident in their expression 
of MYH11 and functional behavior in response to vasoconstrictors. This is beneficial for 
baseline modeling of the healthy arteriole phenotype seen in vivo and could possibly be 
manipulated for disease modeling.   
  
 61 
Chapter 4. Modeling Marfan syndrome using TEBV with directly 
reprogrammed smooth muscle cells 
4.1 Abstract 
 Marfan Syndrome (MFS) is a rare genetic disorder caused by a mutation in the fibrillin-1 
gene, a major component of extracellular microfibrils. While degree of damage might vary, 
patients with MFS often suffer from thoracic aortic aneurysm. Recent clinical trials with losartan 
on MFS patients showed insignificant results in attenuating aortic aneurysm despite its success in 
pre-clinical studies involving MFS mouse models. A fabrication of human cell-based tissue 
engineered blood vessel (TEBV) that can accurately depict the disease characteristics and 
produce relevant drug-induced physiological response would be a better pre-clinical model for 
more efficient drug screening. Here we fabricated a TEBV made up of directly reprogrammed 
smooth muscle cells (SMC) derived from a MFS patient. The resulting MFS TEBV showed 
reduced fibrillin deposition, increased vessel diameter and thickness, and reduced 
vasoconstriction levels when compared to the wild type TEBV. Losartan improved the partial 
functions of MFS TEBV, but still at reduced level when compared to that of the wild type. 
Another drug candidate, SB203580, showed improved vessel function and reduced vessel 
diameter to a level comparable to that of the wild type. 
  
4.2 Introduction 
An in vitro microphysiological system made up of tissue engineered blood vessels 
(TEBV) for disease modeling and drug screening should be capable of accurately depicting the 
pathological phenotype and producing relevant drug-induced physiological responses. The 
system will be even more significant if the resulting drug-induced physiological response can 
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match an existing human clinical study data and corrects the inaccuracy shown in animal models 
due to cross-species discrepancy. To illustrate this, we have investigated into a vascular disease 
called Marfan syndrome (MFS) and its potential drug candidates, losartan and SB203580. 
MFS is a rare genetic disorder caused by a mutation in the fibrillin-1 (FBN1) gene that 
occurs in 1 in 5000 people 116. Although the degree of damage might vary amount patients, 
thoracic aortic aneurysm (TAA) is one of the leading cause of death for patients with MFS. 
Fibrillin-1 is a major component of extracellular microfibrils. Among its various structural and 
regulatory roles in the ECM is its interaction with the latent TGFb-binding proteins (LTBP) to 
create a large latent complexes (LLC) that can bind the bioactive TGFb117. This binding 
interaction thus regulates the availability of TGFb molecules and ensure proper concentration is 
released to the cells for normal cellular processes. However, a mutation in fibrillin-1 causes loss-
of-function phenotype that disables the interaction of LLC and thereby creates an uncontrolled 
release of TGFb. The pathophysiology of how TAA is developed from this abnormal TGFb 
activity or FBN1 mutation in general is unclear as studies from mouse models have indicated 
conflicting results. Some studies have speculated that this TGFb over-production leads to TAA 
progression through the non-canonical extracellular signal-regulated kinase (ERK) signaling 
pathway, and is associated with the angiotensin II receptor type 1 (AT1R) activity117-119. In 
accordance with these studies, Habashi et al. showed that losartan, a AT1R antagonist, could 
prevent TAA formation in the MFS mouse model118.  
The success with preclinical studies have led to multiple clinical trials world-wide, 
including a study by Lacro et al. in the US that compared losartan to a non-specific beta blocker, 
atenolol120,121. However, these all resulted in either a no significance over atenolol, or mixed 
results that have led to conclusion in overall that losartan is an ineffective treatment for MFS 
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patients. This clearly shows a need for a more accurate human-based pre-clinical model that can 
help us better verify the efficacy of a drug candidate, and even further, to understand the 
pathophysiology behind the disease progression. In efforts to address this need, a recent study by 
Granata et al. used MFS patient derived iPSC to differentiate into SMC that displayed the 
appropriate pathological phenotype8. The authors showed that losartan could only partially 
restore the SMC phenotype for human MFS-SMC8, and corroborated other studies that 
postulated TGFb may plate a stage-specific role (i.e. losartan works effective on earlier stages of 
TAA progression but not on the later stage)122. Further, they implicated the role of p38 in the 
TGFb signaling pathway to suggest SB203580, a p38 MAPK inhibitor, as a novel therapeutic 
target. In fact, several other studies have also highlighted the role of abnormal accumulation of 
p38 MAPK leading to increase in Smad2/3 signaling that contributes to aortic aneurysm 
independent of TGFb receptor signaling. Interestingly, Granata et al. also indicated that the p38 
activation is increased under cyclic stretch8, which implicates how dysfunctional mechanical 
properties of the medial layer play a role in TAA progression. In this sense, modeling the MFS 
pathological phenotype at a tissue level with a perfusion system should give more appropriate 
biomechanical cues. Thus, a tissue construct made up of MFS patient derived cell sources can 
potentially offer higher physiological relevance and deeper insights into MFS and TAA that 
cannot be depicted at a cellular level.  
In previous chapters, we have explored the appropriate cell sources for TEBV and 
methods to optimize the fabrication of TEBV. In terms of creating a patient-derived TEBV for 
modeling vascular disease, it was necessary to use SMC as a cell source due to its essential role 
in vascular disease progression. Thus, as discussed in chapter 2, direct reprogramming approach 
through MYOCD overexpression was applied to generate functional iSMC. Dermal fibroblasts 
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from patients and healthy donor were used as a starting cell source due to its wide availability. 
With SMC selected as a cell source, TEBV fabrication method using nanopatterned cell sheet 
that heavily relies on the cell source’s ability to secrete ECM was not applicable since SMC 
inherently have low proliferation and ECM secretion capability than other cell sources such as 
MSC. On the other hand, fabrication method involving dense collagen hydrogel is not dependent 
on the cell type being embedded, and the fabrication process is much faster than the cell sheet 
method, which increases the practicality in terms of its usage in drug screening applications.  
Thus, in this study, we have directly converted patient dermal fibroblasts into iSMC 
using MYOCD overexpression, and subsequently generated TEBV using iSMC and dense 
collagen hydrogel (Figure 11A). The pathological characteristics of MFS were accurately 
depicted at cellular level in iSMCMFS in terms of reduced contractility, and at tissue level in the 
iSMCMFS TEBV in terms of reduced contractility, reduced fibrillin-1 expression, and the 
presence of vessel aneurysm. The iSMCMFS TEBV system was also capable of producing 
accurate response to two different drug candidates, losartan and SB203580.  
 
4.3 Materials and methods 
1. Cell culture methods. 
Human adult dermal fibroblasts (ATCC) and MFS dermal fibroblasts (Coriell, 
GM21944) were cultured in complete DMEM media containing DMEM-HG (Life 
Technologies), 10% FBS (Atlanta Biologicals), 100U/mL Penicillin/Streptomycin (Life 
Technologies), 100U/mL non-essential amino acids (Life Technologies), 100U/mL sodium 
pyruvate (Life Technologies), and 1X 2-mercaptoethanol (Life Technologies). For calcium 
transient activity experiments, smooth muscle differentiation culture media was used (Medium 
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231 with Smooth Muscle Growth Supplement, Life Technologies). EPC was isolated and 
cultured as previously described49,54. Unless stated otherwise, media was changed every other 
day for all cell types and experiments. The lentivirus production and transduction methods for 
the direct reprogramming of fibroblasts to SMC followed the procedure previously described in 
chapter 2, section 3.3, but at the virus MOI of 15 for all subsequent experiments following initial 
MOI test.  
 
2. Characterization of iSMCMFS. 
Immunofluorescent staining of iSMCwt and iSMCMFS followed the same procedure and 
materials as described in chapter 2, section 3.4. Additionally, primary antibody anti-Fibrillin-1 
(Millipore Sigma, MAB2502) was used. For gene expression analysis, the primers for SMC 
markers used were listed in chapter 2, section 3.4. Total RNA was collected using DirectZol 
RNA MiniPrep Plus (Zymo Research), and converted to cDNA using iScript cDNA Synthesis 
Kit (Bio-Rad). Quantitative RT.PCR analysis was performed on Stratagen Mx3005P real-time 
PCR machine using the SSoAdvanced Universal SYBR Green Supermix (Bio-Rad). The 
Stratagen MxPro software was used to analyze the raw data, and additional analysis was 
performed on Microsoft Excel. Relative quantification was performed using the ΔΔCt method 
and statistical significance was determined using the Student’s t-test. 
To prepare for calcium transient activity, fibroblasts were seeded on two 10cm cell 
culture dish, 1X106 cells each for each cell type (wild type and MFS). The next day, cells were 
transduced for direct reprogramming with virus titer of MOI 15 as previously described in 
chapter 2, section 3.3. After 24 hours post-transduction, cells were passaged onto 35mm plates 
(8X104cells/plate) and induced for MYOCD over-expression through the addition of 2µg/ml 
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doxycycline. At day 4 post-DOX induction, cells were transduced with RGECO-1 (described in 
chapter 2, section 3.6), and changed media at day 5. At day 7 post-DOX induction, calcium 
transient activity was measured for half the plates of each experiment groups. For the other 
remaining half, DOX was removed from the culture media and cultured for another 7 days, at 
which point the calcium transient activity was measured. Calcium transient activity was 
measured as described in chapter 2, section 3.6, but with the following modifications: 
commercially available Tyrode’s solution (Sigma, T2397) was used; 50mM KCl, 1µM 
phenylephrine, and 100µM phenylephrine were used for direct addition onto cells and the time 
point at which each addition was made were separately recorded; Nikon A1RMP confocal 
microscope was used for the monitoring and recording of the cells.  
 
3. Characterization of iSMCMFS TEBV 
The assembly of dense collagen gel construct for generating iSMC TEBV followed the 
same procedure described in chapter 3, section 3.3. The vasoactive response of iSMCwt and 
iSMCMFS TEBV to drugs, phenylephrine and caffeine, and flow-rate increase also followed the 
procedure described in chapter 3, section 3.2, but with the modification that 1µM caffeine was 
used for additional vasoconstriction, and no vasodilation was assessed.  
After the functional tests, TEBV were taken out from the chamber, and cut along the 
diameter, so that one part was fixed for histological analysis, whereas the other part was lysed for 
RNA isolation and gene expression analysis. For histological analysis part, the TEBV part was 
further cut in half along the diameter to produce a cross-section specimen, and the other half was 
cut again in longitudinal axis to expose the vessel lumen for longitudinal-section specimen. The 
sections were then fixed in 4% paraformaldehyde (Electron Microscopy Sciences) for 24 hours 
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and in 70% ethanol for 24 hours before being processed for paraffin-embedded sections, H&E, 
and pentachrome staining (processed by the Columbia Molecular Pathology Core). For 
immunofluorescent staining against CNN1, paraffin-embedded sections were processed for 
deparaffinization according to Abcam’s protocol, and underwent antigen retrieval step using 
antigen unmasking solution (Vector Laboratories, H-3300) and microwave for 20 minutes. After 
cooling and washing steps with tap water and PBS, sections were processed for further staining 
according to procedure described in chapter 2, section 3.4. 
The TEBV outer diameter was measured using screenshots from the AmScope recording 
with a known length as a reference. The vessel wall thickness was measured from the histology 
sections as described in a previous study123, and the inner diameter was calculated by subtracting 
the wall thickness from the outer diameter.   
 
4. Drug response iSMCMFS TEBV to losartan and SB203580 
After 7 days of DOX-induction and continuous perfusion, iSMCMFS TEBV were 
subjected to an addition of 1µM of the drug candidate (losartan or SB203580) in the DOX-
removed standard media for additional 7 days before any functional tests were conducted. 
iSMCMFS TEBV of the same culture condition but without losartan was used as a control group. 
Functional tests and histological analysis were performed as described in chapter 4, section 3.3. 
 
4.4 Results 
Following the same direct reprogramming approach as described in chapter 2, dermal 
fibroblasts isolated from MFS patients and healthy donor (wild-type control) were directly 
converted into iSMC through MYOCD over-expression using the doxycycline-inducible 
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lentiviral delivery system. The transduced cells displayed significant phenotypical change within 
7 days post-MYOCD induction. The cell morphology transformed from a narrow, spindle shape 
to a broader, rhomboidal shape often seen in contractile SMC. Immunofluorescence staining 
against SMC markers CNN1 and ACTA2 showed high levels of expression (as indicated by the 
fluorescence intensity) in transduced cells with virus MOI of 15 for both wild type and patient 
cells (Figure 11 C and D). No CNN1 expression was visible in the fibroblasts of both wild type 
and patient cells, and while ACTA2 expression was present, it was to a much lesser extent than 
that shown in the transduced cells. Virus MOI higher than 25 caused cytotoxicity and cell death, 
and since MOI 15 could induce significant phenotypical transformation in the transduced cells, 
the virus MOI of 15 was used for the remainder of the experiments. 
 
Figure 11. Direct conversion of normal and MFS patient dermal fibroblasts to iSMC using 
MYOCD. (A) Illustration depicting the experimental design of our study. (B) Gene expression levels of 
SMC-specific genes ACTA2, CNN1 and MYH11 in wild type fibroblasts (Fbwt), patient fibroblasts 
(FbMFS), iSMCwt and iSMCMFS. (C) Immunofluorescent staining against SMC markers CNN1 and ACTA2 
for wild type and patient fibroblasts transduced with MYOCD virus at multiplicity of infection (MOI) of 
0, 15, and 20.  
	
The gene expression analysis using quantitative RT-PCR for SMC-specific genes in 
transduced cells also showed a similar trend (Figure 11B). The SMC contractile genes CNN1, 
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MYH11, and ACTA2 were all significantly upregulated in transduced cells with induced 
MYOCD over-expression for 7 days compared to the fibroblasts, which indicates a shift towards 
contractile SMC phenotype. Interestingly, the gene expression levels for definitive SMC markers 
CNN1 and MYH11 were slightly higher in iSMCMFS than that of iSMCwt (~2.7X for CNN1 and 
~1.8X for MYH11). This is consistent with previous findings that indicate higher expression 
levels of contractile genes in SMCMFS due to the high levels of active TGFb in the system8. 
ACTA2, which is a more general SMC marker that is also expressed in fibroblasts, was 
expressed higher in the iSMCwt than in iSMCMFS (~3.2X). However, the starting levels of 
ACTA2 were much higher in the wild type fibroblast than patient fibroblast, and when compared 
MFS patient fibroblast to iSMCMFS, the induced expression change was higher in case of patient 
cells (~600X) than that of the wild-type cells (~200X). 
The functional defect of iSMCMFS was assessed by performing the calcium transient 
activity assay described in chapter 2 (Figure 12). Here, each cell groups were monitored for 
calcium response after 7 days of culturing in appropriate conditions. Similar to the results shown 
in chapter 2, a local injection of 50mM KCl, 1µM and 100µM phenylephrine induced a 
contractile response (as measured by fluorescence intensity change) in both iSMCwt and 
iSMCMFS (Figure 12A). In contrast, both wild type and MFS patient fibroblasts did not show any 
fluorescence change in response to stimuli. This suggests that direct reprogramming to SMC has 
been successful in terms of appropriate contractility.  
The fluorescence intensity change in response to 1µM phenylephrine for each cell group 
was then evaluated to compare the difference in calcium transient activity caused by MFS. The 
fluorescence intensity change peaked at ~600-fold for iSMCwt cultured in SMC differentiation 
media (DM), and ~800-fold for iSMCMFS cultured in DM. However, the response duration for 
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iSMCMFS (17.5 s) was significantly less than that for iSMCwt (43 s). The addition of 1µM 
phenylephrine also caused a significant increase in fluorescence for wild type fibroblasts cultured 
in DM, suggesting a shift towards SMC phenotype even without MYOCD overexpression. 
Interestingly, wild type fibroblasts cultured in DM showed a striking resemblance to iSMCMFS 
cultured in DM in terms of peak response time (28 s and 28.75 s) and duration (17.5 s and 18 s) 
(Figure 12B). On the other hand, culturing MFS patient fibroblasts in DM did not cause any 
fluorescence intensity change in response to stimuli as it had done with wild type fibroblast in 
DM. These results suggest that iSMCwt produces a more mature contractile response than the 
iSMCMFS and wild type fibroblast in DM groups, and that MYOCD overexpression in iSMCMFS 
can induce contractile response similar to that caused by DM culture induction in wild type 
fibroblast, but not enough to match that of iSMCwt.     
In addition, iSMCwt in DM after 1 week of continuous DOX-induced MYOCD 
overexpression followed by additional 1 week of standard culture without DOX showed 
significantly faster peak response (16 s) to 1µM phenylephrine than any other groups, suggesting 
a further conversion into mature and functional SMC (Figure 12B). iSMCMFS in DM after 1 week 
of continuous DOX and 1 week of DOX removal did not show a significant peak response to 
1uM phenylephrine, which is significantly different from that of the iSMCwt under same 





       
 
 
Figure 12. iSMCMFS display abnormalities corresponding to the MFS disease characteristics. (A) 
Qualitative and quantitative output of calcium transient wave mapping in iSMCwt and iSMCMFS cultured in 
SMC differentiation media (DM) after 7 days post-MYOCD induction (left), and after 14 days where 
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doxycycline was removed after 7 days. RGB images highlight cells of interest (numbered circles) at the 
peak change in fluorescent intensity (RGECO-1) outlined on the graphs (dotted box). The graphs show 
the change in calcium influx in the highlighted cells over time in response to the indicated substances as 
measured by the change in fluorescent intensity (RGECO-1) of the highlighted cells. (B) The comparison 
of calcium wave in response to 1uM phenylephrine for varying cell groups as indicated. Baseline was 
normalized to background level of each cell group before the addition of phenylephrine for direct 
comparison. Peak response time measures the width of the peak period (at each of half maximum points). 
Response duration measures the time to reach the maximum intensity from the start point.  
 
To evaluate and compare the function of iSMCwt and iSMCMFS at tissue level, TEBV was 
fabricated using dense collagen gel and perfused for 1 week as described in the methods section. 
Normal EPC was used to comprise the TEBV lumen as described in chapter 3. H&E and 
pentachrome staining of iSMCMFS TEBV showed that the overall vessel structure, such as SMC 
density or the presence of collagen, was similar to that of iSMCwt TEBV (Figure 13C). TUNEL 
assay also shows that amount of apoptosis was not significantly different between iSMCwt and 
iSMCMFS TEBV. Immunofluorescence staining against SMC marker CNN1 also indicated high 
expression in both iSMCwt and iSMCMFS TEBV.  
Because MFS is caused by a mutation in fibrillin-1 that results in a loss-of-function 
phenotype, SMCMFS have lower levels of fibrillin-1 expression as compared to that of SMCwt. 
Thus, immunofluorescence staining against fibrillin-1 was performed to assess whether the 
pathological phenotype was present in iSMCMFS (Figure 13C). Consistent with previous reports, 
iSMCMFS TEBV showed much reduced level of fibrillin-1 expression than that of iSMCwt TEBV. 
In contrast, immunofluorescence staining against collagen IV, a common ECM protein, showed 
high expression in both iSMCwt and iSMCMFS TEBV, suggesting lack of extracellular protein 
expression was specific to fibrillin-1. Interestingly, on our initial cell culture studies, 
immunofluorescence staining against fibrillin-1 in iSMCwt and iSMCMFS after 7 days of MYOCD 
induction showed a much lower expression level than what was shown in the previous study8 
even for iSMCwt (Figure 14). It is hypothesized that this lack of fibrillin expression could be due 
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to the lack of cell density in the current 2D experiment conditions (i.e. low seeding density to 
optimize virus transduction) to allow for adequate accumulation of ECM including the fibrillin. 
To test this, iSMC derived from neonatal human dermal fibroblasts (nHDF), which have higher 
proliferation rate than adult fibroblasts, were assessed for fibrillin expression under same 
experiment conditions. Indeed, fibrillin-1 expression was relatively much higher in iSMCnHDF 
than in the iSMC from adult fibroblast (Figure 14). Since TEBV setting allows for a much higher 
cell density (initial seeding of 3 million cells), there is a higher secretion of ECM, which allows 
for better analysis of the ECM protein expression than that of the 2D cell culture studies as 
shown in Figure 13C with iSMCwt TEBV.   
In addition, consistent with the known MFS phenotype characterization, iSMCMFS TEBV 
demonstrated vessel aneurysm when compared to iSMCwt TEBV. iSMCMFS TEBV had an outer 
diameter of 3.86 ± 0.05 mm, inner diameter of 3.40 ± 0.06 mm and vessel wall thickness of 
453.79 ± 43.30 µm, which was significantly larger than that of iSMCwt TEBV with an outer 
diameter of 2.76 ± 0.38 mm, inner diameter of 2.48 ± 0.38 mm and vessel wall thickness of 
279.94 ± 35.19 µm (**, p < 0.005; Figure 13A). Collagen gel constructs with low cell density 
can expand to a higher extent under flow conditions compared to those with higher cell density, 
because they lack the force exerted by the contractile cells to withstand the shear stress. 
However, the cell density calculated from the histological staining of the TEBV sections showed 
that iSMCwt TEBV had density of 9.8x105 cells/mm3 and iSMCMFS TEBV had 9.5x105 
cells/mm3, suggesting that collagen expansion due to lack of cell density was not the major cause 
of vessel aneurysm shown in iSMCMFS TEBV.  
The vasoactive response of iSMCwt and iSMCMFS TEBV was also examined in response 
to 1µM caffeine, 1µM phenylephrine, and increased flow (0 to 2 mL/min) (Figure 13B). In 
 74 
response to caffeine, iSMCwt TEBV constricted by 3.61 ± 0.65%, while iSMCMFS TEBV 
constricted at a significantly lower level of 1.68 ± 0.20% (*, p<0.05). In response to 
phenylephrine, iSMCwt TEBV constricted by 3.17 ± 0.18%, but iSMCMFS TEBV dilated by 0.91 
± 0.17%, which suggest a significant reduction in the vasoactive response (***, p<0.001). In 
response to flow, iSMCwt TEBV expanded by 5.6 ± 0.93%, whereas iSMCMFS TEBV expanded 
by 20.4 ± 2.88% (*, p<0.05). The reduced levels of contractility in iSMCMFS TEBV shown here 






Figure 13. iSMCMFS TEBV display abnormalities corresponding to the MFS disease characteristics. 
(A) Measurements of medial wall thickness, outer diameter (O.D.) and inner diameter (I.D.) of iSMCwt 
and iSMCMFS TEBV. The images of iSMCwt and iSMCMFS TEBV demonstrate the distinct difference their 
outer diameter. (B) Vasoactivity levels of iSMCwt and iSMCMFS TEBV measured by the vessel diameter 
change in response to vasoconstrictor drugs, 1uM phenylephrine (left) and 1uM caffeine (right). (C) 
Histological analysis of iSMCwt and iSMCMFS TEBV with pentachrome, H&E, TUNEL, and 
immunofluorescent staining against CNN1, Collagen IV, and FBN1. Brown arrows in TUNEL images 





Figure 14. Fibrillin-1 protein expression in iSMC in 2D cell culture setting. Fibrillin-1 deposition as 
determined by immunostaining against FBN1 in iSMC derived from wild type nHDF and adHDF, and 
MFS patient. 
	
The effect of potential drug candidates for MFS, losartan and SB203580, on the iSMCMFS 
TEBV phenotype and function was evaluated (Figure 15). iSMCMFS TEBV was cultured for 1 
week on continuous perfusion with DOX-induction followed by addition of either 1µM losartan 
or SB203580 for additional 1 week without DOX induction. iSMCMFS TEBV without any drug 
was used as a negative control. H&E and pentachrome staining showed that both losartan and 
SB203580 did not have a distinct effect on the overall vessel structure of iSMCMFS TEBV 
(Figure 15A). The TUNEL assay also showed no distinct difference in iSMCMFS TEBV treated 
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with SB203580, while more apoptotic cells were present in iSMCMFS TEBV treated with 
losartan. Immunofluorescence staining against fibrillin-1 showed that treatment with losartan did 
not have an effect on fibrillin-1 expression in iSMCMFS TEBV, while SB203580 treatment 
increased fibrillin-1 expression.  
Measurements for TEBV diameters and vessel wall thickness showed that iSMCMFS 
TEBV with 1µM losartan had an outer diameter of 3.68 ± 0.45mm, inner diameter of 3.19 ± 
0.45mm and vessel wall thickness of 468.82 ± 14.41µm, while iSMCMFS TEBV with 1µM 
SB203580 had outer diameter of 3.42 ± 0.10mm, inner diameter of 3.11 ± 0.13mm and vessel 
wall thickness of 309.96 ± 72.29µm (Figure 15B). The treatment with losartan did not reduce the 
iSMCMFS TEBV’s outer diameter or the vessel wall thickness when compared to iSMCMFS 
TEBV without treatment, and they were still significantly different from that of the iSMCwt 
TEBV (*, p<0.05 for outer diameter and **, p < 0.005 for wall thickness). However, the 
treatment with SB203580 decreased iSMCMFS TEBV’s vessel wall thickness significantly (*, 
p<0.05), and the levels were comparable to that of the iSMCwt TEBV. The outer diameter of 
iSMCMFS TEBV with SB203580 treatment was not significantly different from both iSMCMFS 
and iSMCwt TEBV.  
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Figure 15. Drug response of iSMCMFS TEBV to 1uM losartan and 1uM SB203580. (A) Histological 
analysis of iSMCMFTEBV, iSMCMFTEBV with losartan, and iSMCMFTEBV with SB203580 with 
pentachrome, H&E, TUNEL, and anti-FBN1. (B) Vasoactivity levels of all TEBV groups, iSMCwt 
(positive control), iSMCMFS (negative control), iSMCMFTEBV with losartan, and iSMCMFTEBV with 
SB203580, in response to 1uM phenylephrine (top) and 1uM caffeine (bottom).  
 
Drug-mediated vasoconstriction results showed that in response to 1µM phenylephrine, 
iSMCMFS TEBV with 1µM losartan constricted by 2.05 ± 0.40%, and iSMCMFS TEBV with 1µM 
SB203580 constricted by 3.46 ± 0.25% (Figure 15C). While the vasoconstriction level of 
iSMCMFS TEBV treated with 1µM losartan improved in comparison to iSMCMFS TEBV control, 
it was still significantly different from that of iSMCwt TEBV (*, p < 0.05). On the other hand, 
iSMCMFS TEBV treated with 1µM SB203580 showed improved constriction levels comparable 
to that of iSMCwt TEBV (Figure 15C). In response to 1µM caffeine, iSMCMFS TEBV with 1µM 
losartan constricted by 3.33 ± 0.56%, and iSMCMFS TEBV with 1µM SB203580 constricted by 
2.96 ± 0.30%. In both drug groups, the amount of vasoconstriction improved to levels 
comparable to that of iSMCwt TEBV.  
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4.5 Discussion 
A patient-derived in vitro tissue model can provide an accurate depiction of the disease 
characteristics with deeper insights into the disease mechanism than 2D cell culture studies and a 
higher physiological relevance than animal models. In addition, such engineered human tissue 
models can be valuable for a reliable screening of drug candidates prior to clinical trials and 
therefore increase the success rate in clinical trials. In this study, we have successfully fabricated 
TEBV using directly reprogrammed iSMC derived from Marfan syndrome patients. The 
generated iSMCMFS TEBV accurately depicted the pathological characteristics of MFS in terms 
of reduced contractility, reduced fibrillin-1 expression, and the presence of vessel aneurysm. The 
TEBV system was also capable of drug screening by showing response to two different drug 
candidates, losartan and SB203580.   
 The direct reprogramming approach to obtain iSMC involves the overexpression of 
MYOCD. The genetic mutation in fibrillin-1 causes increased bioavailability of TGF-ß1, a 
protein that is involved in many cellular functions, including the SMC differentiation and 
contraction pathway that involves MYOCD. Thus, the abnormal TGF-ß1 activity associated with 
MFS disease could possibly have an effect on the MYOCD-induced direct conversion process. 
Because MYOCD interacts with SRF in a CArG-dependent manner to initiate SMC 
differentiation, the overexpression of MYOCD to induce CArG-dependent transcription would 
be independent to the genetic mutation in fibrillin-1 and increased bioavailability of TGF-ß1. 
While some studies have reported that MYOCD is also involved in the TGF-ß1-induced SMC 
differentiation through its interaction with Smad3, later studies have demonstrated that MYOCD 
is not involved in the initiation of this pathway, but rather interact with Smad3 at a later stage to 
enforce SMC differentiation124. These results indicate that the MYOCD-induced direct 
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reprogramming process will likely be unaffected by the MFS disease characteristics. Indeed, our 
results showed that MYOCD overexpression successfully converted patient fibroblasts into 
iSMC with increased SMC-related gene and protein expression levels (Figure 11) and presence 
of cell contraction in response to vasoactive stimuli (Figure 12).  
 Conversely, the overexpression of MYOCD could have an effect on TGF-ß1 activity and 
consequently the MFS disease characteristics, specifically the vessel aneurysm. Because the role 
of TGF-ß1 signaling in MFS remains controversial, it is also difficult to dissect whether 
MYOCD could be associated with TGF-ß1 to possibly influence aneurysm growth. One 
fundamental study by Holm et al demonstrated using MFS mouse models that the noncanonical 
(Smad-independent) TGF-ß1 signaling is the prominent driver of MFS-mediated thoracic aortic 
aneurysm formation119. Other studies have claimed that aneurysm growth is also regulated by the 
canonical TGF-ß1 signaling, with p-Smad2 accumulation responsible for the media 
degeneration122. As mentioned, previous study that explored the role of MYOCD in TGF-ß1 
signaling revealed MYOCD interacts with Smad3, but not Smad2, in terms of SMC gene 
regulation125. These studies imply that MYOCD seem to interact with TGF-ß1 through a 
pathway that is not associated with those responsible for the MFS aneurysm formation. Indeed, a 
previous study by Granata et al. added TGF-ß1 in their differentiation protocol to obtain SMC 
from MFS patient derived iPSC, but this TGF-ß1 treatment did not affect the MFS disease 
characteristics8. Similarly, our iSMCMFS demonstrated reduced levels of fibrillin-1 expression, 
reduced contractility and presence of vessel aneurysm, which all correspond to the MFS disease 
characteristics. Altogether these results indicate that direct reprogramming approach through 
MYOCD overexpression is a reliable means to obtain patient-derived SMC source for disease 
modeling.  
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Notably, the gene expression levels of CNN1 and MYH11 in iSMCMFS were higher than 
that in iSMCwt. This finding is consistent with previous studies that reported higher SMC 
contractile gene expression, potentially due to increased TGF-ß1 bioavailability. However, 
although MFS disease characteristics led to increased SMC contractile gene expression level, 
this did not translate to the functional level. Our assessment of iSMC contractile function using 
calcium imaging assay showed that iSMCMFS had reduced contractility in response to vasoactive 
stimuli when compared to iSMCwt. While both iSMCwt and iSMCMFS responded to vasoactive 
stimuli such as KCl and phenylephrine, the response duration was much shorter in iSMCMFS than 
in iSMCwt. The time taken to reach the peak response was also much shorter in iSMCwt at 2 
weeks with doxycycline removed, which suggests cells matured over time even in the absence of 
continuous MYOCD overexpression. However, this was not the case for iSMCMFS, which did not 
respond to the addition of 1µM phenylephrine, but only at a higher concentration of 100µM 
phenylephrine. In addition, SMC differentiation media could induce wild type fibroblasts 
towards a SMC contractile phenotype, but not with MFS patient fibroblasts. In fact, iSMCMFS 
demonstrated calcium activity that was strikingly similar to that shown by wild type fibroblasts 
in DM. These results indicate that iSMCMFS lack the level of functional maturity shown in 
iSMCwt because of the MFS disease characteristics. This is consistent with previous reports on 
MFS SMC8,126. Interestingly, consistent with previous calcium imaging studies with native SMC, 
propagating calcium waves were also observed within each cell (both iSMCwt and iSMCMFS) 
continuously during each response, but such wave was not shown in wild type fibroblasts in DM. 
This indicates that while there is a difference in the level of contractility, both iSMCwt and 
iSMCMFS are indeed capable of SMC contractile function. The propagating waves within a cell 
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was not represented in the fluorescence intensity change plot that measures the average intensity 
value of the entire cell area.  
Generating a TEBV using iSMCMFS provides a more biomimetic environment to study 
the MFS disease characteristics. The incorporation of media perfusion through the TEBV lumen 
further mimics the native blood vessel environment, and this would be highly advantageous for 
predicting SMC function in vivo since many of SMC-related gene and proteins are highly 
sensitive to biomechanical stimuli. Further, TEBV allows for better analysis of the ECM secreted 
by the cells as TEBV requires a large cell number than 2D cell culture studies. This is especially 
essential for characterizing MFS as the genetic mutation lies in fibrillin-1, a major component of 
extracellular microfibrils. Our results showed that TEBV was indeed a better setting to study 
fibrillin-1 protein expression in iSMCMFS than 2D cell culture studies.  
While many of previous studies have cultured their TEBV system for up to 4 weeks 
solely for maturation purposes, our iSMC have already been induced to a mature contractile 
phenotype with very low proliferation using MYOCD overexpression, so long term culture does 
not contribute to further maturation. Our initial studies using iSMC TEBV cultured for 1 to 4 
weeks with conditions equal to previous studies prove that long term perfusion is not a suitable 
method for maturation in case of iSMC TEBV system. This result is also consistent with 
previous SMC differentiation studies that add the growth factor TGF-ß1 to finally induce SMC 
into a mature contractile phenotype, but the amount induced by lentiviral delivery of MYOCD 
overexpression is significantly higher than that by a growth factor addition. As a method to 
further improve our TEBV system, we have increased the initial cell seeding density of our 
TEBV construct compared to previous studies. The higher cell density TEBV produces higher 
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ECM production, and with 1 week of perfusion, the resulting TEBV has shown to produce a 
substantial outcome in terms of TEBV function and disease modeling.  
The most distinct characteristic of MFS blood vessels is the presence of vessel aneurysm. 
Our iSMCMFS TEBV could depict this disease phenotype by producing larger outer and inner 
diameter and vessel wall thickness when compared to iSMCwt TEBV. Our histological analysis 
and vasoactivity testing demonstrated that the only significant difference between the iSMCMFS 
TEBV and iSMCwt TEBV that could be correlated with the presence of aneurysm in iSMCMFS 
TEBV was the reduced cell contractility and lack of fibrillin-1 deposition in comparison to 
iSMCwt TEBV, and this is consistent with the known MFS disease characteristics.  
 To assess the capability of our TEBV system as an in vitro drug screening platform, we 
administered losartan and SB203580, two different drugs that were previously shown to 
attenuate aortic aneurysm in MFS mouse models, on iSMCMFS TEBV. Losartan is an angiotensin 
II type I specific receptor (AT1R) blocker that has been shown to prevent the effects of abnormal 
TGF-ß1 signaling activity and attenuate aortic root dilation in MFS mice models, but 
unfortunately showed insignificant results in human clinical trials. SB203580 is a p38 MAPK 
inhibitor that has been shown to attenuate angiotensin II stimulation of Smad-2 phosphorylation 
independent of TGF-ß1 activity and therefore suggested in recent studies to help attenuate the 
MFS symptoms. Our results showed that treatment of iSMCMFS TEBV with losartan partially 
improved the vessel contractility in terms of its response to 1µM caffeine, but caused no 
significant improvement in terms of vessel aneurysm and fibrillin-1 deposition. Furthermore, 
TUNEL analysis showed presence of more apoptotic cells in iSMCMFS TEBV with losartan. 
These results are consistent with clinical trial results that show losartan did not have a significant 
effect on reducing aneurysm. On the other hand, the treatment of iSMCMFS TEBV with 
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SB203580 significantly reduced vessel aneurysm in terms of the vessel wall thickness to a level 
comparable to that of the iSMCwt TEBV, and increased the amount of fibrillin-1 deposition when 
compared to iSMCMFS TEBV without any treatment. In addition, the contractility response to 
both 1µM phenylephrine and caffeine also improved to a level comparable to that of the iSMCwt 
TEBV. These results also confirm with previous studies that showed positive effects of 
SB203580 on improving the symptoms of MFS disease characteristics.  
Mouse models are valuable tools that have helped us tremendously in understanding 
various disease mechanism, including MFS where mouse model was used to discover that 
abnormal activity in TGF- ß1 signaling pathway is the prominent driver of vessel aneurysm. 
However, it is also true that MFS mouse models failed to accurately depict the human 
physiological response to losartan and has resulted in waste of resources and time for clinical 
studies. Thus, it is critical that we have another in vitro model made up of human tissues that can 
complement and eventually replace mouse models for preclinical studies. Currently, only 
losartan has progressed to clinical trials for treating MFS, and yet it has resulted in disappointing 
outcome. Thus, there is clearly a need for more accurate in vitro drug screening platform, and the 
results from our TEBV system with losartan, which replicates the human clinical trial results, 
and SB203580, which shows improvement over losartan, demonstrates that our system can 
provide a better insight into drug’s efficacy compared to previous 2D cell culture studies and 
animal models.  
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Chapter 5. Conclusion 
In this thesis, we have explored different cell sources and fabrication methods to 
successfully create a human cell-based TEBV system suitable for in vitro microphysiological 
system. Once such parameters have been optimized, we then demonstrated the capability of the 
designed TEBV system in modeling a vascular disease called Marfan Sydrome for drug screening 
purposes.  
Due to the practical issues with utilizing native SMC as vascular wall source for TEBV, 
alternative cell sources needed to be explored. First, MSC was used as a cell source to fabricate 
an aligned cell sheet that could generate a scaffold-free TEBV construct. Second, reprogrammed 
SMC was obtained by the direct conversion of human EPC to iSMC through MYOCD 
overexpression. iSMC showed cytoskeletal arrangement that was significantly different from the 
EPC and more similar to the mesenchymal cells, and by day 7 iSMC showed upregulation of 
smooth muscle markers in terms of gene and protein expression analysis. The global gene 
expression of iSMC resembled umbilical artery SMC. In terms of function, iSMC showed 
contraction in response to vasoactive stimuli such as phenylephrine, and a contraction force 
similar to umbilical artery SMC.  
 While numerous methods exist for the fabrication of a TEBV, selecting a method that can 
achieve equally high levels of functional, biocompatible and mechanical properties can be 
difficult. Here we assessed two different fabrication methods while prioritizing its usage as in 
vitro microphysiological system for disease modeling and drug screening. First, a scaffold-free 
TEBV was constructed from aligned human MSC cell sheets and human EPC for the vascular 
wall and lumen, respectively. The mechanical strength of the TEBV was assessed in terms of the 
burst pressure, which was at normal physiological levels. The structural integrity of the TEBV 
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resembled that of the native blood vessel in terms of cell layer organization and ECM formation. 
The vasoactive function of the TEBV was confirmed through flow-mediated vasodilation, drug-
mediated vasoconstriction and nitric oxide release all at a manner similar to that of porcine 
femoral vein. The monocyte adhesion activity indicated presence of a functional endothelium.  
Second, a TEBV was constructed using a dense collagen hydrogel where iSMC was directly 
embedded to the collagen solution prior to the gelation. The resulting iSMC TEBV showed 
appropriate functionality with respect to flow- and drug- mediated vasodilation and 
vasoconstriction. 
 Finally, to illustrate that our optimized TEBV system can accurately depict disease 
characteristics and produce relevant drug-induced physiological response, a TEBV was 
fabricated using iSMC derived from a MFS patient. The resulting MFS TEBV showed reduced 
fibrillin deposition, increased vessel diameter and thickness, and reduced vasoconstriction levels 
when compared to the wild type TEBV. Losartan could only improve the functions of MFS 
TEBV partially, and SB203580 showed slightly better improvement than losartan and the levels 
were comparable to that of the wild type. 
 In the future, we will test out more types of drug compounds on our system. By using 
available pharmaceutical drug compounds, it is possible to demonstrate the potential of the 
TEBV system as an effective pre-clinical trial model. Moreover, the results from our TEBV 
work will allow us to better understand disease mechanisms and drug metabolism, and ultimately 
help create a more effective and safer drug. In addition, we propose to extend our TEBV system 
to test multiple patient samples to ensure its robustness and versatility. We currently have 
multiple MFS patient specimens both as fibroblasts and peripheral blood mononuclear cells. 
These patient specimens will be directly converted to iSMC, and a TEBV will be constructed 
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using these cells to carry out analysis as shown in this thesis. Further, the availability of iSMC 
and TEBV data from multiple donors creates an opportunity for studying direct reprogramming 
in depth. Currently, only few studies have studied the epigenetic stability for directly 
reprogrammed cells 127. A recent study developed a network biology platform called CellNet to 
compare the gene regulatory network (GRN) profile of reprogrammed cells with the donor and 
target cell types 128. This study showed that induced neurons and cardiomyocytes obtained from 
the direct transdifferentiation method 45,129 were incompletely converted as they failed to 
adequately silence donor cell GRN. However, the extent of impact these activated donor cell 
GRN have on the target cell function, and whether these GRN get silenced over time remains to 
be explored. We propose to apply CellNet and transcriptome analysis to address these concerns 
and investigate the epigenetic profile of iSMC. The availability of multiple MFS patient 
specimens can maximize our assessment of donor-dependent genetic variation in iSMC and 
ensure a reliable and appropriate usage of iSMC as a vascular model. Finally, insights gained 
from the epigenetic analysis may help identify new target regions and enhance the direct 
reprogramming efficiency. This is an attractive approach as more recent reprogramming studies 
have begun exploring epigenetic regulators in place of exogenous transcription factors for 
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